<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1119" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1119/" /><meta name="ncbi_pagename" content="Dystrophinopathies - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Dystrophinopathies - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Dystrophinopathies" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/04/26" /><meta name="citation_author" content="Basil T Darras" /><meta name="citation_author" content="David K Urion" /><meta name="citation_author" content="Partha S Ghosh" /><meta name="citation_pmid" content="20301298" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1119/" /><meta name="citation_keywords" content="Duchenne Muscular Dystrophy (DMD)" /><meta name="citation_keywords" content="Becker Muscular Dystrophy (BMD)" /><meta name="citation_keywords" content="DMD-Associated Dilated Cardiomyopathy" /><meta name="citation_keywords" content="Dystrophin" /><meta name="citation_keywords" content="DMD" /><meta name="citation_keywords" content="Dystrophinopathies" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Dystrophinopathies" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Basil T Darras" /><meta name="DC.Contributor" content="David K Urion" /><meta name="DC.Contributor" content="Partha S Ghosh" /><meta name="DC.Date" content="2018/04/26" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1119/" /><meta name="description" content="The dystrophinopathies cover a spectrum of X-linked muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of creatine phosphokinase (CK) and muscle cramps with myoglobinuria. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne/Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated dilated cardiomyopathy (DCM) when the heart is primarily affected." /><meta name="og:title" content="Dystrophinopathies" /><meta name="og:type" content="book" /><meta name="og:description" content="The dystrophinopathies cover a spectrum of X-linked muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of creatine phosphokinase (CK) and muscle cramps with myoglobinuria. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne/Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated dilated cardiomyopathy (DCM) when the heart is primarily affected." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1119/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/dbmd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1119/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CAD00E03FDC7100000000079B02AE.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1119_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1119_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ebd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eed-og/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1119_"><span class="title" itemprop="name">Dystrophinopathies</span></h1><p class="contrib-group"><span itemprop="author">Basil T Darras</span>, MD, <span itemprop="author">David K Urion</span>, MD, and <span itemprop="author">Partha S Ghosh</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1119_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1119_ai__"><div class="contrib half_rhythm"><span itemprop="author">Basil T Darras</span>, MD<div class="affiliation small">Director, Neuromuscular Center<br />Department of Neurology<br />Boston Children&#x02019;s Hospital<br />Harvard Medical School<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dravrah.snerdlihc@sarrad.lisab" class="oemail">ude.dravrah.snerdlihc@sarrad.lisab</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">David K Urion</span>, MD<div class="affiliation small">Department of Neurology<br />Boston Children&#x02019;s Hospital<br />Harvard Medical School<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dravrah.snerdlihc@noiru.divad" class="oemail">ude.dravrah.snerdlihc@noiru.divad</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Partha S Ghosh</span>, MD<div class="affiliation small">Neuromuscular Center<br />Department of Neurology<br />Boston Children&#x02019;s Hospital<br />Harvard Medical School<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dravrah.snerdlihc@hsohg.ahtrap" class="oemail">ude.dravrah.snerdlihc@hsohg.ahtrap</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 5, 2000</span>; Last Update: <span itemprop="dateModified">April 26, 2018</span>.</p><p><em>Estimated reading time: 50 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="dbmd.Summary" itemprop="description"><h2 id="_dbmd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The dystrophinopathies cover a spectrum of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and <i>DMD</i>-associated dilated cardiomyopathy (DCM). The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of creatine phosphokinase (CK) and muscle cramps with myoglobinuria. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne/Becker muscular dystrophy when skeletal muscle is primarily affected and as <i>DMD</i>-associated dilated cardiomyopathy (DCM) when the heart is primarily affected.</p><p>Duchenne muscular dystrophy (DMD) usually presents in early childhood with delayed motor milestones including delays in walking independently and standing up from a supine position. Proximal weakness causes a waddling gait and difficulty climbing stairs, running, jumping, and standing up from a squatting position. DMD is rapidly progressive, with <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children being wheelchair dependent by age 12 years. Cardiomyopathy occurs in almost all individuals with DMD after age 18 years. Few survive beyond the third decade, with respiratory complications and progressive cardiomyopathy being common causes of death.</p><p>Becker muscular dystrophy (BMD) is characterized by later-onset skeletal muscle weakness. With improved diagnostic techniques, it has been recognized that the mild end of the spectrum includes men with onset of symptoms after age 30 years who remain ambulatory even into their 60s. Despite the milder skeletal muscle involvement, heart failure from DCM is a common cause of morbidity and the most common cause of death in BMD. Mean age of death is in the mid-40s.</p><p><i>DMD</i>-associated DCM is characterized by left ventricular dilation and congestive heart failure. Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at increased risk for DCM.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of a dystrophinopathy is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the characteristic clinical findings and elevated CK concentration and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>DMD</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in a male and of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variant in <i>DMD</i> on molecular genetic testing in a female. Females may present with a classic dystrophinopathy or may be asymptomatic carriers.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> ACE inhibitors are used with or without beta blockers for cardiomyopathy in both DMD and BMD phenotypes. Congestive heart failure is treated with diuretics and oxygen as needed; cardiac transplantation is offered to persons with severe dilated cardiomyopathy and BMD with limited or no clinical evidence of skeletal muscle disease. Scoliosis is treated with bracing and surgery. Corticosteroid therapy improves muscle strength and function for individuals with DMD between ages five and 15 years; the same treatment is used in BMD, although the efficacy is less clear.</p><p><i>Prevention of secondary complications:</i> Evaluation by a pulmonologist and cardiologist before surgeries; pneumococcal and influenza immunizations annually; nutrition assessment; physical therapy to promote mobility and prevent contractures; sunshine and a balanced diet rich in vitamin D and calcium to improve bone density and reduce the risk of fractures; weight control to avoid obesity.</p><p><i>Surveillance:</i> For males with DMD or BMD: annual or biannual evaluation by a cardiologist beginning at the time of diagnosis; monitoring for scoliosis; baseline pulmonary function testing before wheelchair dependence; frequent evaluations by a pediatric pulmonologist. For <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females: cardiac evaluation at least once after the teenage years.</p><p><i>Agents/circumstances to avoid:</i> Botulinum toxin injections; succinylcholine and inhalational anesthetics because of susceptibility to malignant hyperthermia or malignant hyperthermia-like reactions.</p><p><i>Evaluation of relatives at risk:</i> Early identification of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females who are at increased risk for cardiomyopathy and, thus, need routine cardiac surveillance and prompt treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>The dystrophinopathies are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. The risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the mother. Heterozygous females have a 50% chance of transmitting the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy. Sons who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; daughters who inherit the pathogenic variant are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and may have a range of clinical manifestations. Males with DMD usually do not reproduce. Males with BMD or <i>DMD</i>-associated DCM may reproduce: all of their daughters are heterozygotes; none of their sons inherit their father's <i>DMD</i> pathogenic variant. Carrier testing for at-risk females and prenatal testing or <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for pregnancies at increased risk are possible if the <i>DMD</i> pathogenic variant in the family is known.</p></div></div><div id="dbmd.GeneReview_Scope"><h2 id="_dbmd_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="dbmd.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dbmd.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophinopathies: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_dbmd.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Duchenne muscular dystrophy (DMD)</div></li><li class="half_rhythm"><div>Becker muscular dystrophy (BMD)</div></li><li class="half_rhythm"><div><i>DMD</i>-associated dilated cardiomyopathy</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#dbmd.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="dbmd.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#dbmd.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="dbmd.Diagnosis"><h2 id="_dbmd_Diagnosis_">Diagnosis</h2><p>The dystrophinopathies cover a spectrum of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> muscle disease that ranges from mild to severe and includes Duchenne muscular dystrophy, Becker muscular dystrophy, and <i>DMD</i>-associated dilated cardiomyopathy (DCM).</p><div id="dbmd.Suggestive_Findings"><h3>Suggestive Findings</h3><p>A dystrophinopathy <b>should be suspected</b> in an individual with the following <a href="#dbmd.Clinical_Findings">clinical</a> and <a href="#dbmd.Laboratory_Testing">laboratory test</a> findings that support the diagnosis of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or <i>DMD</i>-associated dilated cardiomyopathy (DCM) &#x02013; especially when they occur in addition to a positive family history compatible with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance. Findings are most commonly noted in males, but females may also be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><div id="dbmd.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Duchenne muscular dystrophy (DMD)</b></p><ul><li class="half_rhythm"><div>Progressive symmetric muscle weakness (proximal &#x0003e; distal) often with calf hypertrophy</div></li><li class="half_rhythm"><div>Symptoms present before age five years</div></li><li class="half_rhythm"><div>Wheelchair dependency before age 13 years</div></li></ul><p><b>Becker muscular dystrophy (BMD)</b></p><ul><li class="half_rhythm"><div>Progressive symmetric muscle weakness (proximal &#x0003e; distal) often with calf hypertrophy; weakness of quadriceps femoris in some cases the only sign</div></li><li class="half_rhythm"><div>Activity-induced cramping (present in some individuals)</div></li><li class="half_rhythm"><div>Flexion contractures of the elbows (if present, late in the course)</div></li><li class="half_rhythm"><div>Wheelchair dependency (after age 16 years); although some individuals remain ambulatory into their 30s and in rare cases into their 40s and beyond</div></li><li class="half_rhythm"><div>Preservation of neck flexor muscle strength (differentiates BMD from DMD)</div></li></ul><p>Note: The presence of fasciculations or loss of sensory modalities excludes a suspected diagnosis of a dystrophinopathy. Individuals with an intermediate <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (outliers) have symptoms of intermediate severity and become wheelchair dependent between ages 13 and 16 years.</p><p><b><i>DMD</i>-associated dilated cardiomyopathy (DCM)</b></p><ul><li class="half_rhythm"><div>Dilated cardiomyopathy (DCM) with congestive heart failure, with males typically presenting between ages 20 and 40 years and females presenting later in life</div></li><li class="half_rhythm"><div>Usually no clinical evidence of skeletal muscle disease; may be classified as "subclinical" BMD</div></li><li class="half_rhythm"><div>Rapid progression to death in several years in males and slower progression over a decade or more in females [<a class="bk_pop" href="#dbmd.REF.beggs.1997.2344">Beggs 1997</a>]</div></li></ul><p>See also <a href="/books/n/gene/dcm-ov/">Dilated Cardiomyopathy Overview</a>.</p></div><div id="dbmd.Laboratory_Testing"><h4>Laboratory Testing</h4><p><b>Serum creatine phosphokinase (CK) concentration</b> (<a class="figpopup" href="/books/NBK1119/table/dbmd.T.serum_creatine_phosphokinase_ck_c/?report=objectonly" target="object" rid-figpopup="figdbmdTserumcreatinephosphokinaseckc" rid-ob="figobdbmdTserumcreatinephosphokinaseckc">Table 1</a>)</p><div id="dbmd.T.serum_creatine_phosphokinase_ck_c" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Serum Creatine Phosphokinase (CK) Concentration in the Dystrophinopathies</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.T.serum_creatine_phosphokinase_ck_c/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.T.serum_creatine_phosphokinase_ck_c_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Affected Individuals</th><th id="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum CK Concentration</th></tr></thead><tbody><tr><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Males</b></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DMD</td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>1</sup></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;10x normal</td></tr><tr><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">BMD</td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>1</sup></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;5x normal</td></tr><tr><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>DMD</i>-associated DCM</td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most individuals&#x000a0;<sup>2</sup></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">"Increased"</td></tr><tr><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Female carriers</b></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DMD</td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50%&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-10x normal</td></tr><tr><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">BMD</td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~30%&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_dbmd.T.serum_creatine_phosphokinase_ck_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-10x normal</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="dbmd.TF.1.1"><p class="no_margin">Serum CK concentration gradually decreases with advancing age as a result of the progressive elimination of dystrophic muscle fibers that are the source of the elevated serum CK concentration [<a class="bk_pop" href="#dbmd.REF.hoffman.1988.1363">Hoffman et al 1988</a>, <a class="bk_pop" href="#dbmd.REF.zatz.1991.190">Zatz et al 1991</a>].</p></div></dd><dt>2. </dt><dd><div id="dbmd.TF.1.2"><p class="no_margin">Serum CK concentrations are usually increased, but normal concentrations have been reported in <i>DMD</i>-associated DCM [<a class="bk_pop" href="#dbmd.REF.mestroni.1999.181">Mestroni et al 1999</a>].</p></div></dd><dt>3. </dt><dd><div id="dbmd.TF.1.3"><p class="no_margin"><a class="bk_pop" href="#dbmd.REF.hoogerwaard.1999b.347">Hoogerwaard et al [1999b]</a></p></div></dd><dt>4. </dt><dd><div id="dbmd.TF.1.4"><p class="no_margin">Other investigations have confirmed a wide variability in serum CK concentration among DMD/BMD carriers with the mean serum CK concentration significantly higher in carriers age &#x0003c;20 years than in those age &#x0003e;20 years [<a class="bk_pop" href="#dbmd.REF.sumita.1998.356">Sumita et al 1998</a>].</p></div></dd></dl></div></div></div></div></div><div id="dbmd.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of a dystrophinopathy <b>is established</b> in a male proband with the characteristic clinical findings and elevated CK concentration and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>DMD</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1119/table/dbmd.T.serum_creatine_phosphokinase_ck_c/?report=objectonly" target="object" rid-figpopup="figdbmdTserumcreatinephosphokinaseckc" rid-ob="figobdbmdTserumcreatinephosphokinaseckc">Table 1</a>).</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of a dystrophinopathy <b>is usually established</b> in a female proband with characteristic clinical findings and elevated CK concentration and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>DMD</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1119/table/dbmd.T.serum_creatine_phosphokinase_ck_c/?report=objectonly" target="object" rid-figpopup="figdbmdTserumcreatinephosphokinaseckc" rid-ob="figobdbmdTserumcreatinephosphokinaseckc">Table 1</a>).</p><p>Females may present with a classic dystrophinopathy or may be asymptomatic carriers.</p><ul><li class="half_rhythm"><div><b>Females with a classic dystrophinopathy.</b> The genetic mechanisms that can explain this rare occurrence (and testing to identify the cause) include the following:</div><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> involving Xp21.2 (microarray [CMA] studies)</div></li><li class="half_rhythm"><div>An X-<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> rearrangement involving Xp21.2 or complete absence of an X chromosome (i.e., Turner syndrome) (<a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> studies)</div></li><li class="half_rhythm"><div>Uniparental disomy (UPD) of the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> (UPD studies)</div></li><li class="half_rhythm"><div>Compound heterozygosity for two <i>DMD</i> pathogenic variants [<a class="bk_pop" href="#dbmd.REF.soltanzadeh.2010.499">Soltanzadeh et al 2010</a>] (<a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>)</div></li><li class="half_rhythm"><div>Nonrandom <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> (XCI). See <a href="#dbmd.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</div></li></ul></li><li class="half_rhythm"><div><b>Carrier testing for at-risk female relatives.</b> Note: Carriers are heterozygotes for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder and may later develop clinical findings related to the disorder (see <a href="#dbmd.Clinical_Characteristics">Clinical Characteristics</a> and Management, <a href="#dbmd.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for testing recommendations).</div></li></ul><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Because the majority of pathogenic variants involve deletions of one or more exons, gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>DMD</i> is performed first and followed by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>DMD</i> and other genes of interest (see <a href="#dbmd.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div><div class="half_rhythm"><b>Note:</b> (1) A <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> may be most appropriate for individuals with less severe clinical presentations. Men with the BMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and most women may not have findings clinically distinct enough to suggest single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing of <i>DMD</i> as the initial test. (2) <b>Chromosomal microarray analysis</b> (CMA) may:</div><ul><li class="half_rhythm"><div>Be appropriate if not already performed, to identify multiple <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications (including <i>DMD</i>);</div></li><li class="half_rhythm"><div>Be considered first in an individual presenting with additional medical concerns associated with known <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorders such as <a href="/books/n/gene/rp-overview/">retinitis pigmentosa</a>, <a href="/books/n/gene/cgd/">chronic granulomatous disease</a>, and McLeod red cell <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (see <a href="/books/n/gene/mcleod/">McLeod neuroacanthocytosis syndrome</a>) [<a class="bk_pop" href="#dbmd.REF.francke.1985.250">Francke et al 1985</a>] or glycerol kinase deficiency and <a href="/books/n/gene/ahc/">adrenal hypoplasia</a> [<a class="bk_pop" href="#dbmd.REF.darras.1988.126">Darras &#x00026; Francke 1988</a>] to suggest a contiguous <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> disorder;</div></li><li class="half_rhythm"><div>Detect an unexpected or incidental <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> in an asymptomatic individual.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered, particularly if the presentation is atypical. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div><div class="half_rhythm">Exome array (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is nondiagnostic given the frequency of DMD deletions or duplications associated with dystrophinopathy.</div></li></ul><div id="dbmd.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Dystrophinopathies</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>DMD</i></td><td headers="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-35%</td></tr><tr><td headers="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_dbmd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">65%-80%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="dbmd.TF.2.1"><p class="no_margin">See <a href="/books/NBK1119/#dbmd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="dbmd.TF.2.2"><p class="no_margin">See <a href="#dbmd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="dbmd.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="dbmd.TF.2.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="dbmd.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="dbmd.TF.2.6"><p class="no_margin">Chromosomal microarray analysis (CMA) may detect <i>DMD</i> deletions or duplications either as part of a <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion-syndrome/">contiguous gene deletion syndrome</a> or as an incidental or unexpected intragenic finding. Given that the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of CMA is not sufficient to detect all <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-level <i>DMD</i> deletions and duplications, CMA is not recommended as a primary assay for dystrophinopathies.</p></div></dd></dl></div></div></div><p>Note: If no <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, skeletal muscle biopsy of individuals with suspected DMD or BMD is warranted for western blot and immunohistochemistry studies of dystrophin. Skeletal muscle biopsy continues to be used only rarely in the diagnosis of dystrophinopathies.</p><ul><li class="half_rhythm"><div><b>Muscle histology</b> early in the disease shows nonspecific dystrophic changes, including variation in fiber size, foci of necrosis and regeneration, hyalinization, increased internal nuclei, fiber splitting, inflammatory changes, and, later in the disease, deposition of fat and connective tissue.</div></li><li class="half_rhythm"><div><b>Western blot and immunohistochemistry</b> are summarized in <a class="figpopup" href="/books/NBK1119/table/dbmd.T.findings_in_the_dystrophin_protei/?report=objectonly" target="object" rid-figpopup="figdbmdTfindingsinthedystrophinprotei" rid-ob="figobdbmdTfindingsinthedystrophinprotei">Table 3</a>.</div></li></ul><div id="dbmd.T.findings_in_the_dystrophin_protei" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Findings in the Dystrophin Protein from Skeletal Muscle Biopsy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.T.findings_in_the_dystrophin_protei/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.T.findings_in_the_dystrophin_protei_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Western Blot</th><th id="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" style="text-align:left;vertical-align:middle;">Immunohistochemistry&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3" id="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Dystrophin Mol Wt&#x000a0;<sup>1</sup></th><th headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3" id="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophin Quantity&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Males</b></td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DMD</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Undetectable</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-5%</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete or almost complete absence</td></tr><tr><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Intermediate</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal/<br />abnormal</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-20%</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">BMD</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-50%</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Normal appearing or reduced intensity &#x000b1; patchy staining</td></tr><tr><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Abnormal</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-100%</td></tr><tr><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Heterozygous</b><br /><b>Females</b></td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DMD random XCI&#x000a0;<sup>4</sup></td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal/<br />abnormal</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;60%&#x000a0;<sup>5,&#x000a0;6</sup> (70%&#x000b1;9%)</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal or minor changes or mosaic pattern;<br />dystrophin-negative fibers (9%&#x000b1;2%)&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">DMD skewed XCI&#x000a0;<sup>7</sup></td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal/<br />abnormal</td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_3 hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;30% on average (29%&#x000b1;25%)&#x000a0;<sup>5</sup></td><td headers="hd_h_dbmd.T.findings_in_the_dystrophin_protei_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mosaic pattern;<br />dystrophin-negative fibers (44%&#x000b1;33%)&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Mol Wt = molecular weight; XCI = <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a></p></div></dd><dt>1. </dt><dd><div id="dbmd.TF.3.1"><p class="no_margin">Normal molecular mass is 427 kb.</p></div></dd><dt>2. </dt><dd><div id="dbmd.TF.3.2"><p class="no_margin">The quantity of dystrophin is expressed in percent of control values. The reference ranges shown in this table are the ones currently used by clinical laboratories and reflect approximate and reconciled data from the literature.</p></div></dd><dt>3. </dt><dd><div id="dbmd.TF.3.3"><p class="no_margin">Uses monoclonal antibodies to the C terminus, N terminus, and rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of dystrophin [<a class="bk_pop" href="#dbmd.REF.hoffman.1988.1363">Hoffman et al 1988</a>]</p></div></dd><dt>4. </dt><dd><div id="dbmd.TF.3.4"><p class="no_margin">Asymptomatic to mild disability</p></div></dd><dt>5. </dt><dd><div id="dbmd.TF.3.5"><p class="no_margin"><a class="bk_pop" href="#dbmd.REF.pegoraro.1995.677">Pegoraro et al [1995]</a></p></div></dd><dt>6. </dt><dd><div id="dbmd.TF.3.6"><p class="no_margin">Quantitative analysis of dystrophin in female carriers is not useful in clinical practice because of the wide range of values and the significant overlap with normal values.</p></div></dd><dt>7. </dt><dd><div id="dbmd.TF.3.7"><p class="no_margin">Mild, intermediate, severe symptoms. Carriers with mild disease were young (age 5-10 years) [<a class="bk_pop" href="#dbmd.REF.pegoraro.1995.677">Pegoraro et al 1995</a>].</p></div></dd></dl></div></div></div></div></div><div id="dbmd.Clinical_Characteristics"><h2 id="_dbmd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="dbmd.Clinical_Description"><h3>Clinical Description</h3><div id="dbmd.Males"><h4>Males</h4><p>The dystrophinopathies cover a spectrum of muscle disease that ranges from mild to severe. The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of CK and muscle cramps with myoglobinuria. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) when skeletal muscle is primarily affected and as <i>DMD</i>-associated dilated cardiomyopathy (DCM) when the heart is primarily affected [<a class="bk_pop" href="#dbmd.REF.beggs.1997.2344">Beggs 1997</a>, <a class="bk_pop" href="#dbmd.REF.cox.1997.329">Cox &#x00026; Kunkel 1997</a>, <a class="bk_pop" href="#dbmd.REF.muntoni.2003.731">Muntoni et al 2003</a>].</p><p><b>DMD vs BMD vs <i>DMD</i>-associated DCM.</b> The distinction between DMD and BMD is based on the age of wheelchair dependency: before age 13 years in DMD and after age 16 years in BMD. An intermediate group of individuals who become wheelchair bound between ages 13 and 16 years is also recognized. Additionally, some investigators have extended the mild end of the BMD spectrum to include individuals with elevated serum CK concentration and abnormal dystrophin on muscle biopsy, but with "subclinical" skeletal muscle involvement [<a class="bk_pop" href="#dbmd.REF.melacini.1996.3168">Melacini et al 1996</a>]. When these individuals with atypical disease develop severe cardiomyopathy, it is not possible to distinguish between BMD and <i>DMD</i>-associated DCM [<a class="bk_pop" href="#dbmd.REF.cox.1997.329">Cox &#x00026; Kunkel 1997</a>].</p><p>Cardiac involvement is usually asymptomatic in the early stages of the disease, although sinus tachycardia and various ECG abnormalities may be noted. Echocardiography is normal or shows only regional abnormalities. Pericardial effusion with cardiac tamponade and myocardial inflammation precipitating heart failure has been described in people with DMD [<a class="bk_pop" href="#dbmd.REF.lin.2009.476">Lin et al 2009</a>, <a class="bk_pop" href="#dbmd.REF.mavrogeni.2010.33">Mavrogeni et al 2010</a>]. Subclinical or clinical cardiac involvement is present in approximately 90% of individuals with DMD or BMD; however, cardiac involvement is the cause of death in only 20% of individuals with DMD and 50% of those with BMD [<a class="bk_pop" href="#dbmd.REF.hermans.2010.479">Hermans et al 2010</a>].</p><p><i>DMD</i>-associated DCM generally presents with congestive heart failure secondary to an increase in ventricular size and impairment of ventricular function. In males, DCM is rapidly progressive with onset in teenage years, leading to death from heart failure within one to two years after the diagnosis [<a class="bk_pop" href="#dbmd.REF.finsterer.2003.1">Finsterer &#x00026; Stollberger 2003</a>]. Individuals with DCM may or may not have clinical evidence of skeletal muscle disease [<a class="bk_pop" href="#dbmd.REF.neri.2007.913">Neri et al 2007</a>].</p><p><b>DMD</b></p><p><b>Motor development.</b> DMD usually presents in early childhood with delayed motor milestones, including delays in walking independently and standing up from the floor. The mean age of walking is approximately 18 months (range 12-24 months). The first symptoms of DMD as identified by parents are typically: general motor delays (42%); gait problems including persistent toe-walking and flat-footedness (30%); delay in walking (20%); learning difficulties (5%); and speech problems (3%). The mean age of diagnosis of boys with DMD without a family history of DMD is approximately four years ten months (range: 16 months - 8 years) [<a class="bk_pop" href="#dbmd.REF.bushby.1999.1875">Bushby 1999</a>, <a class="bk_pop" href="#dbmd.REF.zalaudek.1999.1975">Zalaudek et al 1999</a>]. A recent study reported a mean age of 41 months at diagnosis of DMD [<a class="bk_pop" href="#dbmd.REF.damico.2017.447">D'Amico et al 2017</a>]. Proximal weakness causes a waddling gait and difficulty climbing stairs, running, jumping, and standing up from a squatting position [<a class="bk_pop" href="#dbmd.REF.li.2012.746">Li et al 2012</a>, <a class="bk_pop" href="#dbmd.REF.liang.2018.176">Liang et al 2018</a>]. Boys use the Gower maneuver to rise from a supine position, using the arms to supplement weak pelvic girdle muscles. The calf muscles are hypertrophic and firm to palpation. Occasionally there is calf pain. DMD is rapidly progressive, with <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children being wheelchair bound by age 12 years [<a class="bk_pop" href="#dbmd.REF.darras.2015">Darras et al 2015</a>].</p><p><b>Cardiomyopathy.</b> Among children with DMD, the incidence of cardiomyopathy increases steadily in the teenage years, with approximately one third of individuals being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by age 14 years, one half by age 18 years, and all individuals after age 18 years [<a class="bk_pop" href="#dbmd.REF.nigro.1990.271">Nigro et al 1990</a>].</p><p><b>Cognitive abilities.</b> Some degree of non-progressive cognitive impairment in boys with DMD has long been known. This was initially described as a general "leftward shift" in the spectrum of IQ scores of a population with DMD compared to the population at large. Earlier reports had suggested that verbal IQ was more affected than performance IQ on the Wechsler Intelligence Scales.</p><p>A retrospective study by <a class="bk_pop" href="#dbmd.REF.banihani.2015.1472">Banihani et al [2015]</a> demonstrated that in their sample, 27% of the boys had IQ &#x0003c;70, with 19% overall fulfilling all criteria for intellectual disability (ID). A learning disability was present in 44%, attention-deficit hyperactivity disorder (ADHD) in 32%, autism spectrum disorder (ASD) in 15%, and anxiety in 27%. No significant correlation was seen between these neuropsychiatric conditions and dystrophin <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>.</p><p><a class="bk_pop" href="#dbmd.REF.ricotti.2016.77">Ricotti et al [2016]</a> accessed 130 males with DMD from four European centers and reviewed IQ assessment and a screening questionnaire. Of the original 130, 87 then underwent more extensive testing. Comparable rates of ID, ASD, ADHD, learning disability, and anxiety were observed.</p><p>These retrospective studies thus suggest increased rates of ID, ASD, ADHD, and learning disability in boys with DMD compared to the population at large.</p><p><a class="bk_pop" href="#dbmd.REF.battini.2018.122">Battini et al [2018]</a> engaged in a prospective assessment of 40 boys with DMD. Their work showed that in boys without frank ID, executive functions such as multitasking, problem solving, inhibition, and working memory were affected out of proportion to overall cognitive function. They suggested that DMD was therefore associated with deficits in "executive function" in boys who did not demonstrate ID.</p><p>This confirms the retrospective work of <a class="bk_pop" href="#dbmd.REF.wicksell.2004.154">Wicksell et al [2004]</a>, who demonstrated that boys with DMD who did not have ID showed deficits in active working memory in both verbal and visuospatial domains. It also confirms the retrospective study of <a class="bk_pop" href="#dbmd.REF.hinton.2001.45">Hinton et al [2001]</a>, who demonstrated short-term verbal memory issues in boys with DMD who did not have ID.</p><p>All of these studies thus suggest that the earlier allegation of poorer verbal function in boys with DMD and without ID was better explained by deficits in executive function, which could also lead to visuospatial difficulties in certain settings.</p><p><b>Mobility.</b> DMD is associated with reduced mobility. Thus, boys with DMD have decreased bone density and are at increased risk for fractures. Corticosteroids further increase the risk of vertebral compression fractures, many of which are asymptomatic.</p><p><b>Life span.</b> Despite improvement of survival, few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals survive beyond the third decade [<a class="bk_pop" href="#dbmd.REF.passamano.2012.121">Passamano et al 2012</a>]. Respiratory complications and progressive cardiomyopathy are common causes of death. A study of individuals with molecularly confirmed diagnoses has determined a median survival of 24 years, with ventilated patients reaching a median survival of 27 years [<a class="bk_pop" href="#dbmd.REF.rall.2012.117">Rall &#x00026; Grimm 2012</a>]. In a cohort of affected individuals having both spinal surgery and nocturnal ventilation, the median survival was 30 years [<a class="bk_pop" href="#dbmd.REF.eagle.2007.470">Eagle et al 2007</a>]. Because death frequently occurs outside the hospital setting, the cause of death is often difficult to determine [<a class="bk_pop" href="#dbmd.REF.parker.2005.729">Parker et al 2005</a>].</p><p><b>BMD</b></p><p><b>Motor development.</b> BMD is characterized by later-onset skeletal muscle weakness. With improved diagnostic techniques, it has been recognized that the mild end of the spectrum includes men with onset of symptoms after age 30 years who remain ambulatory even into their 60s [<a class="bk_pop" href="#dbmd.REF.yazaki.1999.145">Yazaki et al 1999</a>].</p><p>Mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with confirmatory <i>DMD</i> molecular genetic studies and/or dystrophin studies on muscle biopsy have been classified as having either of the following [<a class="bk_pop" href="#dbmd.REF.melacini.1996.3168">Melacini et al 1996</a>]:</p><ul><li class="half_rhythm"><div>BMD with "subclinical" skeletal muscle involvement in the presence of elevated serum CK concentration, calf hypertrophy, muscle cramps, myalgia, and exertional myoglobinuria</div></li><li class="half_rhythm"><div>"Benign" skeletal muscle involvement when "subclinical" findings are accompanied by muscle weakness in the pelvic girdle and/or shoulder girdle</div></li></ul><p><b>Cardiomyopathy.</b> While skeletal muscle involvement is milder in BMD, heart failure from DCM is a common cause of morbidity and the most common cause of death [<a class="bk_pop" href="#dbmd.REF.cox.1997.329">Cox &#x00026; Kunkel 1997</a>]. Mean age at cardiomyopathy diagnosis is 14.6 years, similar to that in DMD (14.4 years) [<a class="bk_pop" href="#dbmd.REF.connuck.2008.998">Connuck et al 2008</a>]. Heart transplantation rate in BMD is high within five years after the diagnosis of cardiomyopathy [<a class="bk_pop" href="#dbmd.REF.connuck.2008.998">Connuck et al 2008</a>, <a class="bk_pop" href="#dbmd.REF.kamdar.2016.2533">Kamdar &#x00026; Garry 2016</a>]. Mean age of death is in the mid-40s [<a class="bk_pop" href="#dbmd.REF.bushby.1999.1875">Bushby 1999</a>].</p><p><b>Cognitive abilities.</b> Cognitive impairment is not as common or as severe in BMD as in DMD.</p><p><b><i>DMD</i>-associated DCM</b></p><p>In 1987, a five-generation, 63-member family with DCM but no evidence of skeletal myopathy was reported. Males present in their teens and twenties; the disease course is rapidly progressive and associated ventricular arrhythmias are common. Heterozygous females develop mild dilated cardiomyopathy in the fourth or fifth decade, with slow progression. The only biochemical abnormality is elevation in serum CK concentration. <a class="bk_pop" href="#dbmd.REF.towbin.1993.1854">Towbin et al [1993]</a> demonstrated linkage to the dystrophin <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> in this family and one other.</p><p>Subsequent study demonstrated that in individuals with the most severe cardiac <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> the cardiac muscle is usually unable to produce functional dystrophin in the heart, while in skeletal muscle reduced levels of virtually normal dystrophin transcript and protein are present [<a class="bk_pop" href="#dbmd.REF.ferlini.1999.339">Ferlini et al 1999</a>, <a class="bk_pop" href="#dbmd.REF.neri.2007.913">Neri et al 2007</a>, <a class="bk_pop" href="#dbmd.REF.neri.2012.20">Neri et al 2012</a>]; see <a href="#dbmd.Molecular_Genetics">Molecular Genetics</a>.</p><p><i>DMD</i>-associated DCM may be the presenting finding in individuals with BMD who have little or no clinical evidence of skeletal muscle disease. Some investigators classify such individuals as having subclinical or benign BMD, whereas others may classify such individuals as having DCM with increased serum CK concentration [<a class="bk_pop" href="#dbmd.REF.towbin.1998.131">Towbin 1998</a>]. In one study of 28 individuals with subclinical and benign BMD between ages six and 48 years, 19 (68%) had myocardial involvement, although only two were symptomatic [<a class="bk_pop" href="#dbmd.REF.melacini.1996.3168">Melacini et al 1996</a>]. In another study of 21 individuals ranging from age three to 63 years (mean age 40 years), 33% had cardiac failure despite relatively mild skeletal muscle findings [<a class="bk_pop" href="#dbmd.REF.saito.1996.642">Saito et al 1996</a>].</p><p><i>DMD</i> is a relatively infrequent cause of DCM. In a cohort of 99 Japanese unrelated adult males and females with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> and <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> DCM, <i>DMD</i> pathogenic variants were identified in only three males [<a class="bk_pop" href="#dbmd.REF.shimizu.2005.150">Shimizu et al 2005</a>].</p></div><div id="dbmd.Females"><h4>Females</h4><p>In some instances females can have classic DMD (see <a href="#dbmd.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p><p>Signs and symptoms of DMD and BMD were studied among confirmed <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females [<a class="bk_pop" href="#dbmd.REF.hoogerwaard.1999a.2116">Hoogerwaard et al 1999a</a>, <a class="bk_pop" href="#dbmd.REF.hoogerwaard.1999b.347">Hoogerwaard et al 1999b</a>] (<a class="figpopup" href="/books/NBK1119/table/dbmd.T.signs_and_symptoms_in_females_het/?report=objectonly" target="object" rid-figpopup="figdbmdTsignsandsymptomsinfemaleshet" rid-ob="figobdbmdTsignsandsymptomsinfemaleshet">Table 4</a>). In contrast, <a class="bk_pop" href="#dbmd.REF.nolan.2003.129">Nolan et al [2003]</a> found no cardiac abnormalities in 23 proven heterozygotes age 6.2 to 15.9 years (see <a href="#dbmd.Penetrance">Penetrance</a>). The prevalence of cardiomyopathy depends on its definition and can vary from 3% to 33% [<a class="bk_pop" href="#dbmd.REF.mccaffrey.2017.810">Mccaffrey et al 2017</a>]. No correlation of <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (DMD vs BMD), age, CK level, or muscle symptoms was noted. In another study, however, DCM was more common in functionally symptomatic heterozygous females [<a class="bk_pop" href="#dbmd.REF.schade_van_westrum.2011.62">Schade van Westrum et al 2011</a>].</p><div id="dbmd.T.signs_and_symptoms_in_females_het" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Signs and Symptoms in Females Heterozygous for a <i>DMD</i> Pathogenic Variant</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.T.signs_and_symptoms_in_females_het/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.T.signs_and_symptoms_in_females_het_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Signs/Symptoms</th><th id="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In Families with DMD</th><th id="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In Families with BMD</th></tr></thead><tbody><tr><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">76%</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">81%</td></tr><tr><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle weakness&#x000a0;<sup>1</sup></td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19%</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14%</td></tr><tr><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myalgia/cramps</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td></tr><tr><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Left-ventricle dilation</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19%</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%</td></tr><tr><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dilated cardiomyopathy</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td><td headers="hd_h_dbmd.T.signs_and_symptoms_in_females_het_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">From <a class="bk_pop" href="#dbmd.REF.hoogerwaard.1999b.347">Hoogerwaard et al [1999b]</a></p></div></dd><dt>1. </dt><dd><div id="dbmd.TF.4.1"><p class="no_margin">Mild to moderate weakness</p></div></dd></dl></div></div></div></div></div><div id="dbmd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>If a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, the diagnosis of a dystrophinopathy is established, but the distinction between DMD and BMD can be difficult in some cases. For example, <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 3-7, the most extensively investigated deletion associated with both phenotypes, has been found in males with DMD and also with BMD [<a class="bk_pop" href="#dbmd.REF.aartsmarus.2006.135">Aartsma-Rus et al 2006</a>].</p><p><b>Reading frame rule.</b> This "rule" states that pathogenic variants that do not alter the reading frame (<a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions/duplications) generally correlate with the milder BMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, whereas those that alter the reading frame (out-of-frame) generally correlate with the more severe DMD phenotype [<a class="bk_pop" href="#dbmd.REF.monaco.1988.90">Monaco et al 1988</a>]. Therefore, the type of <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> can distinguish between the DMD and BMD phenotypes with 91%-92% accuracy in young children who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) [<a class="bk_pop" href="#dbmd.REF.aartsmarus.2006.135">Aartsma-Rus et al 2006</a>], and in many cases a muscle biopsy is not needed to address the issue of BMD vs DMD.</p><p>Although exceptions to the "reading frame rule" have been documented to occur at a rate below 10% [<a class="bk_pop" href="#dbmd.REF.aartsmarus.2006.135">Aartsma-Rus et al 2006</a>], more recent studies suggest that this may only hold true for the DMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, and that the rate of exception may be higher with the BMD phenotype for both deletions and duplications [<a class="bk_pop" href="#dbmd.REF.kesari.2008.728">Kesari et al 2008</a>, <a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>]. Correlation of clinical features with molecular test results is thus very important.</p><p><b>In males with DMD and BMD,</b> phenotypes are best correlated with the degree of expression of dystrophin, which is largely determined by the reading frame of the spliced message obtained from the deleted <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#dbmd.REF.monaco.1988.90">Monaco et al 1988</a>, <a class="bk_pop" href="#dbmd.REF.koenig.1989.498">Koenig et al 1989</a>].</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>DMD.</b> Very large deletions may lead to absence of dystrophin expression. Pathogenic variants that disrupt the reading frame include stop variants, some <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants, and deletions or duplications. They produce a severely truncated dystrophin protein molecule that is degraded, leading to the more severe DMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Exceptions to this "reading frame rule": deletions in protein-binding domains that may severely affect function even when <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> [<a class="bk_pop" href="#dbmd.REF.hoffman.1991.605">Hoffman et al 1991</a>]; and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-skipping events in which apparently out-of-frame deletions behave as in-frame deletions or vice versa [<a class="bk_pop" href="#dbmd.REF.chelly.1990.1239">Chelly et al 1990</a>]. The accuracy of phenotype prediction using this rule is in the range of 91%-92% [<a class="bk_pop" href="#dbmd.REF.aartsmarus.2006.135">Aartsma-Rus et al 2006</a>]. More recent studies suggest that duplications, which occur more commonly in BMD, may result in exceptions to the reading frame rule in a higher proportion of cases, perhaps up to 30% [<a class="bk_pop" href="#dbmd.REF.kesari.2008.728">Kesari et al 2008</a>, <a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>]. Correlation of clinical features with molecular test results is thus very important.</div><div class="half_rhythm"><a class="bk_pop" href="#dbmd.REF.wingeier.2011.90">Wingeier et al [2011]</a> showed that there was no clear relationship between pathogenic variants seen in males with DMD and specific aspects of cognitive function, or overall performance on standard measures of cognitive abilities. They did note, however, that the lack of the dystrophin isoform Dp140 was associated with greater impairments overall; this observation confirms the findings of a previous study that suggested that dystrophin deletions involving the brain distal isoform Dp140 are associated with intellectual impairment [<a class="bk_pop" href="#dbmd.REF.felisari.2000.559">Felisari et al 2000</a>]. Mild intellectual disability is significantly more common in males with pathogenic variants affecting Dp140; also, most males with pathogenic variants involving the Dp71 isoform are cognitively disabled [<a class="bk_pop" href="#dbmd.REF.daoud.2009.3779">Daoud et al 2009</a>, <a class="bk_pop" href="#dbmd.REF.taylor.2010.e8803">Taylor et al 2010</a>]. Recent work from the French Neuromuscular Network suggests that pathogenic variants in the distal parts of the dystrophin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> are more likely to be associated with cognitive impairment [<a class="bk_pop" href="#dbmd.REF.mercier.2013.855">Mercier et al 2013</a>].</div><div class="half_rhythm">Dp71 and Dp140 are the shorter <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> of dystrophin and are highly expressed in fetal brain with gradual increase from the embryonic stage to adult. Dp71 is very abundant in the hippocampus and some layers of the cerebral cortex with sublocalization in synaptic membranes, microsomes, synaptic vesicles, and mitochondria. The location of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> appears to correlate with full-scale IQ (FSIQ) values (e.g., pathogenic variants affecting the Dp140 isoform 5' UTR affect FSIQ less than those affecting the Dp140 promoter or <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>) [<a class="bk_pop" href="#dbmd.REF.taylor.2010.e8803">Taylor et al 2010</a>]. Further, the cumulative loss of isoforms expressed in the central nervous system increases the risk of cognitive deficit [<a class="bk_pop" href="#dbmd.REF.taylor.2010.e8803">Taylor et al 2010</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>BMD.</b> The BMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> occurs when some dystrophin is produced, usually resulting from deletions or duplications that juxtapose <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> exons, some <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants, and most non-truncating single-base changes that result in translation of a protein product with intact N and C termini. The shorter-than-normal dystrophin protein molecule, which retains partial function, produces the milder BMD phenotype [<a class="bk_pop" href="#dbmd.REF.deburgrave.2007.183">Deburgrave et al 2007</a>].</div><div class="half_rhythm">Exceptions to the reading frame rule occur more commonly in BMD than in DMD. In one large cohort, a BMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> failed to follow the reading frame rule in approximately 15% of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, and approximately 34% of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> [<a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>]. Another study also reported exceptions to the reading frame rule in 30% of males with BMD with a duplication [<a class="bk_pop" href="#dbmd.REF.kesari.2008.728">Kesari et al 2008</a>]. Correlation of clinical features with molecular test results is crucial; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and their families should be informed that using this rule, phenotype prediction may be less accurate.</div><div class="half_rhythm">In men with BMD, deletions involving the amino-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> correlate with early-onset dilated cardiomyopathy (DCM; mid-20s), whereas deletions affecting part of the rod domain and hinge 3 result in a later-onset DCM (mid-40s) [<a class="bk_pop" href="#dbmd.REF.kaspar.2009.544">Kaspar et al 2009</a>].</div></li></ul><p><b><i>DMD</i>-associated DCM</b> is caused by pathogenic variants in <i>DMD</i> that affect the muscle promoter (P<sub>M</sub>) and the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> (E1), resulting in no dystrophin transcripts being produced in cardiac muscle; however, two alternative promoters that are normally only active in the brain (P<sub>B</sub>) and Purkinje cells (P<sub>P</sub>) are active in the skeletal muscle, resulting in dystrophin expression sufficient to prevent manifestation of skeletal muscle symptoms [<a class="bk_pop" href="#dbmd.REF.beggs.1997.2344">Beggs 1997</a>, <a class="bk_pop" href="#dbmd.REF.towbin.1998.131">Towbin 1998</a>, <a class="bk_pop" href="#dbmd.REF.yoshida.1998.1129">Yoshida et al 1998</a>]. Other types of pathogenic variants including a novel rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of exons 13-16 [<a class="bk_pop" href="#dbmd.REF.chamberlain.2015.439">Chamberlain et al 2015</a>], <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, and deletions in the exon 45-53 region of <i>DMD</i> [<a class="bk_pop" href="#dbmd.REF.shimizu.2005.150">Shimizu et al 2005</a>] have been reported in <i>DMD</i>-associated DCM.</p><p><i>DMD</i>-associated DCM may also be caused by alteration of epitopes in a region of the protein of particular functional importance to cardiac muscle [<a class="bk_pop" href="#dbmd.REF.ortizlopez.1997.2434">Ortiz-Lopez et al 1997</a>] or possibly by pathogenic variants in hypothetic cardiac-specific exons.</p><p>Abnormalities in cardiac conduction noted in persons with dystrophinopathies may be related to reduced expression of cardiac sodium channel NA(v)1.5 secondary to dystrophin deficiency [<a class="bk_pop" href="#dbmd.REF.gavillet.2006.407">Gavillet et al 2006</a>].</p><p>See also <a href="/books/n/gene/dcm-ov/">Dilated Cardiomyopathy Overview</a>. The occurrence of either cardiomyopathy or BMD in the same family raises the possibility of modification of the phenotypic expression of a specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by epigenetic factors [<a class="bk_pop" href="#dbmd.REF.palmucci.2000.529">Palmucci et al 2000</a>].</p></div><div id="dbmd.Penetrance"><h3>Penetrance</h3><p>Penetrance of dystrophinopathies is complete in males.</p><p>Penetrance in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females varies, and may depend in part on patterns of <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> (XCI).</p><ul><li class="half_rhythm"><div>Some studies have shown no clear correlation between the active-to-inactive X-<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> ratio observed in XCI studies in leukocytes and serum CK concentration, clinical signs, or the proportion of dystrophin-negative fibers observed on muscle biopsy [<a class="bk_pop" href="#dbmd.REF.sumita.1998.356">Sumita et al 1998</a>].</div></li><li class="half_rhythm"><div>In another study of seven symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, the XCI pattern was skewed toward non-random in the four with deletions or duplications but was random in the three with pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants [<a class="bk_pop" href="#dbmd.REF.soltanzadeh.2010.499">Soltanzadeh et al 2010</a>].</div></li><li class="half_rhythm"><div>In contrast, <a class="bk_pop" href="#dbmd.REF.pegoraro.1995.677">Pegoraro et al [1995]</a> showed that more than 90% of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females with skewed XCI (defined as &#x02265;75% of nuclei harboring the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on the active X-<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a>) as demonstrated from a blood sample develop mild, moderate, or severe muscular dystrophy. Heterozygous females with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> were young (i.e., age 5-10 years).</div></li><li class="half_rhythm"><div>Direct correlation with a skewed XCI pattern was also observed recently in cohorts of symptomatic and asymptomatic DMD/BMD carriers [<a class="bk_pop" href="#dbmd.REF.giliberto.2014.36">Giliberto et al 2014</a>, <a class="bk_pop" href="#dbmd.REF.viggiano.2016.685">Viggiano et al 2016</a>, <a class="bk_pop" href="#dbmd.REF.viggiano.2017">Viggiano et al 2017</a>]. However, because the <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status of the androgen receptor (AR) <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in white blood cells or muscle may not always reflect the methylation status of <i>DMD</i>, the use of the AR methylation assay has limited prognostic value in clinical practice [<a class="bk_pop" href="#dbmd.REF.juanmateu.2012.82">Juan-Mateu et al 2012</a>].</div></li></ul></div><div id="dbmd.Nomenclature"><h3>Nomenclature</h3><p>The term "pseudohypertrophic muscular dystrophy" was used in the past; however, it is not used currently because pseudohypertrophy is not unique to the DMD or BMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div><div id="dbmd.Prevalence"><h3>Prevalence</h3><p>Prevalence data are not available.</p><p>The overall incidence of DMD in Canada (Nova Scotia) is one in 4,700 live male births and has remained stable from 1969 to 2008 [<a class="bk_pop" href="#dbmd.REF.dooley.2010a.177">Dooley et al 2010a</a>].</p><p>The incidence of BMD in northern England is 1:18,450 live male births [<a class="bk_pop" href="#dbmd.REF.bushby.1991.1022">Bushby et al 1991</a>].</p><p>During the years 1968 to 1978, the incidence of DMD in southeast Norway was 1:3,917 live male births [<a class="bk_pop" href="#dbmd.REF.tangsrud.1989.100">Tangsrud &#x00026; Halvorsen 1989</a>].</p></div></div><div id="dbmd.Genetically_Related_Allelic_Disorde"><h2 id="_dbmd_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b>Intellectual disability without muscle weakness.</b> In-frame <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>DMD</i> exons 56-57 (with different dystrophin <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> Dp424m, Dp260, Dp140, and Dp116) has been associated with intellectual disability (ID) without muscle weakness. In addition, three asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females (with <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of exons 13-27, partial deletion of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 46, and deletion of 46-55) were found to have <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> cognitive impairment and no evidence of muscle weakness, suggesting that dystrophinopathy with isolated ID and no evidence of muscle weakness may be more common than had been previously thought [<a class="bk_pop" href="#dbmd.REF.juanmateu.2013.753">Juan-Mateu et al 2013</a>]. Another case of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> ID without muscle weakness was reported in a family with a 3-<a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a>, <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a>, single amino-acid deletion in the brain-specific Dp71 isoform of dystrophin. CK was mildly elevated [<a class="bk_pop" href="#dbmd.REF.de_brouwer.2014.480">de Brouwer et al 2014</a>].</p></div><div id="dbmd.Differential_Diagnosis"><h2 id="_dbmd_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Limb-girdle muscular dystrophy</b>
<b>(LGMD)</b> is a group of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorders that are clinically similar to DMD but occur in both sexes. Limb-girdle dystrophies are caused by mutation of genes that encode sarcoglycans and other proteins associated with the muscle cell membrane that interact with dystrophin [<a class="bk_pop" href="#dbmd.REF.mohassel.2015">Mohassel &#x00026; B&#x000f6;nnemann 2015</a>]. Testing for deficiency of proteins from the transmembrane sarcoglycan complex and of other proteins is indicated in individuals with dystrophin-positive dystrophies. LGMD type 2I phenotypically resembles DMD and BMD and is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FKRP</i> (encoding fukutin-related protein).</p><p><a href="/books/n/gene/edmd/"><b>Emery-Dreifuss muscular dystrophy</b></a>
<b>(EDMD)</b> is characterized by the clinical triad of joint contractures that begin in early childhood, slowly progressive muscle weakness and wasting initially in a humero-peroneal distribution that later extends to the scapular and pelvic girdle muscles, and cardiac involvement that may include palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure. Age of onset, severity, and progression of the muscle and cardiac involvement show intra- and interfamilial variation. Clinical variability ranges from early and severe presentation in childhood to a late onset and slowly progressive course. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade. Pathogenic variants in three genes are known to cause EDMD: <i>EMD</i> and <i>FHL1</i>, which cause <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> EDMD; and <i>LMNA</i>, which causes <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> EDMD and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EDMD.</p><p><a href="/books/n/gene/sma/"><b>Spinal muscular atrophy</b></a>
<b>(SMA)</b> is suspected in individuals with poor muscle tone, muscle weakness that spares the face and ocular muscles, and evidence of anterior horn cell involvement, including fasciculations of the tongue and absence of deep tendon reflexes. The onset of weakness ranges from before birth to adolescence or young adulthood. The weakness is symmetric, proximal &#x0003e; distal, and progressive. Poor weight gain with growth failure, restrictive lung disease, scoliosis, joint contractures, and sleep difficulties are common complications. SMA is caused by pathogenic variants in <i>SMN1</i> and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/dcm-ov/"><b>Dilated cardiomyopathy</b></a>
<b>(DCM)</b> can be <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> or nonfamilial. In a large series in which family studies were performed, one third to one half of individuals had nonfamilial DCM and two thirds had familial DCM. Familial DCM may be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>, or an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. Most familial DCM (probably 80%-90%) appears to be autosomal dominant; X-linked and autosomal recessive forms are less common [<a class="bk_pop" href="#dbmd.REF.watkins.2011.1643">Watkins et al 2011</a>].</p><p><a href="/books/n/gene/barth/"><b>Barth syndrome</b></a><b>,</b> an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder caused by mutation of <i>TAZ</i>, is characterized in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given affected individual. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis or left ventricular non-compaction. Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. The non-progressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a postpubertal growth spurt with remarkable "catch-up" growth.</p></div><div id="dbmd.Management"><h2 id="_dbmd_Management_">Management</h2><div id="dbmd.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with a dystrophinopathy, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Physical therapy assessment</div></li><li class="half_rhythm"><div>Developmental evaluation before entering elementary school for the purpose of designing an individualized educational plan, as necessary</div></li><li class="half_rhythm"><div>At the time of diagnosis or by age six years, evaluation for cardiomyopathy by electrocardiography, cardiac echocardiography, and/or MRI [<a class="bk_pop" href="#dbmd.REF.towbin.2003.317">Towbin 2003</a>, <a class="bk_pop" href="#dbmd.REF.bushby.2010b.177">Bushby et al 2010b</a>]</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="dbmd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Appropriate management of individuals with a dystrophinopathy can prolong survival and improve quality of life.</p><div id="dbmd.DMDBMD_Phenotypes"><h4>DMD/BMD Phenotypes</h4><p><b>Cardiomyopathy.</b> Recommendations are based on an American Academy of Pediatrics policy statement and various additional publications [<a class="bk_pop" href="#dbmd.REF1">American Academy of Pediatrics Section on Cardiology and Cardiac Surgery 2005</a>, <a class="bk_pop" href="#dbmd.REF.jefferies.2005.2799">Jefferies et al 2005</a>, <a class="bk_pop" href="#dbmd.REF.viollet.2012.98">Viollet et al 2012</a>] and apply to patients with the DMD or BMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><ul><li class="half_rhythm"><div>The authors' institution commonly treats children with DMD or BMD early with an ACE inhibitor and/or beta blocker.</div></li><li class="half_rhythm"><div>When used in combination, these appear to lead to initial improvement of left ventricular function; however, ACE inhibitors are also used without beta blockers, with similar results [<a class="bk_pop" href="#dbmd.REF.viollet.2012.98">Viollet et al 2012</a>].</div></li><li class="half_rhythm"><div>The optimal time to start treatment in DMD is unknown, but most cardiologists will initiate treatment when the left ventricle ejection fraction drops below 55% and fractional shortening is less than 28% [<a class="bk_pop" href="#dbmd.REF.jefferies.2005.2799">Jefferies et al 2005</a>, <a class="bk_pop" href="#dbmd.REF.viollet.2012.98">Viollet et al 2012</a>].</div></li><li class="half_rhythm"><div>Angiotensin II-receptor blockers (ARBs) such as losartan are similarly effective and can be used in cases of poor tolerability of ACE inhibitors [<a class="bk_pop" href="#dbmd.REF.allen.2013">Allen et al 2013</a>].</div></li><li class="half_rhythm"><div>In cases of overt heart failure, other heart failure therapies including diuretics and digoxin are used as needed.</div></li><li class="half_rhythm"><div>Cardiac transplantation is offered to persons with severe dilated cardiomyopathy and BMD with limited or no clinical evidence of skeletal muscle disease.</div></li></ul><p><b>Scoliosis</b> treatment as needed is appropriate. The management of scoliosis involves bracing and surgery. Most patients end up getting a spinal fusion. The use of rods is not contraindicated; therefore, rod and bone grafts are used to fuse the spine. A minority of patients do not develop significant scoliosis and may not require a spinal fusion.</p><p><b>Corticosteroid therapy.</b> Studies have shown that corticosteroids improve the muscle strength and function of individuals with DMD (see <a href="/books/NBK1119/bin/dbmd-corticosteroids.pdf">Corticosteroid Therapy in DMD</a>). This therapy remains the treatment of choice for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals between ages five and 15 years. Corticosteroid therapy is not recommended in children before age two years [<a class="bk_pop" href="#dbmd.REF.bushby.2010a.77">Bushby et al 2010a</a>]. This treatment is also used in BMD, although the efficacy is less clear (see <b>BMD</b> below).</p><p>The following published recommendations for corticosteroid therapy are in accordance with the national practice parameters developed by the American Academy of Neurology and the Child Neurology Society [<a class="bk_pop" href="#dbmd.REF.moxley.2005">Moxley et al 2005</a>] (<a href="http://www.neurology.org/content/64/1/13.long" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>), as well as the DMD Care Considerations Working Group [<a class="bk_pop" href="#dbmd.REF.bushby.2010a.77">Bushby et al 2010a</a>].</p><ul><li class="half_rhythm"><div>Boys with DMD should be offered treatment with prednisone (0.75 mg/kg/day, maximum daily dose: 30-40 mg) or deflazacort (0.9 mg/kg/day, maximum daily dose: 36-39 mg) as soon as plateauing or decline in motor skills is noted, which usually occurs at age 4-8 years. Prior to the initiation of therapy, the potential benefits and risks of corticosteroid treatment should be carefully discussed with each individual.</div></li><li class="half_rhythm"><div>To assess benefits of corticosteroid therapy, the following parameters are useful: timed muscle function tests, pulmonary function tests, and age at loss of independent ambulation.</div></li><li class="half_rhythm"><div>To assess risks of corticosteroid therapy, maintain awareness of the potential corticosteroid therapy side effects (e.g., weight gain, cushingoid appearance, short stature, decrease in linear growth, acne, excessive hair growth, gastrointestinal symptoms, behavioral changes). There is also an increased frequency of vertebral and long bone fractures with prolonged corticosteroid use [<a class="bk_pop" href="#dbmd.REF.king.2007.1607">King et al 2007</a>].</div></li><li class="half_rhythm"><div>The optimal maintenance dose of prednisone (0.75 mg/kg/day) or deflazacort (0.9 mg/kg/day) should be continued if side effects are not severe. Significant but less robust improvement can be seen with gradual tapering of prednisone to as low as 0.3 mg/kg/day (or ~0.4 mg/kg/day of deflazacort).</div></li><li class="half_rhythm"><div>If excessive weight gain occurs (&#x0003e;20% over estimated normal weight for height over a 12-month period), the prednisone dose should be decreased by 25%-33% and reassessed in a few months. If excessive weight gain continues, the dose should be further decreased by an additional 25% to the minimum effective dose cited above after three to four months.</div></li><li class="half_rhythm"><div>If significant weight gain or intolerable behavioral side effects occur in patients treated with prednisone, change to deflazacort on a ten-day-on / ten-day-off schedule or a high-dose weekend schedule. In patients on deflazacort, side effects of asymptomatic cataracts and weight gain should be monitored.</div></li></ul><p><b>BMD.</b> Information about the efficacy of prednisone in treating individuals with BMD is limited. Many clinicians continue treatment with glucocorticoids after loss of ambulation for the purpose of maintaining upper limb strength, delaying the progressive decline of respiratory and cardiac function, and decreasing the risk of scoliosis. Retrospective data suggest that the progression of scoliosis can be reduced by long-term daily corticosteroid treatment; however, an increased risk for vertebral and lower-limb fractures has been documented [<a class="bk_pop" href="#dbmd.REF.king.2007.1607">King et al 2007</a>]. Men on steroid therapy were less likely to require spinal surgery [<a class="bk_pop" href="#dbmd.REF.dooley.2010b.173">Dooley et al 2010b</a>]. The dose is allowed to drift down to 0.3-0.6 mg/kg/day of prednisone or deflazacort, which is still effective [<a class="bk_pop" href="#dbmd.REF.bushby.2010a.77">Bushby et al 2010a</a>].</p></div><div id="dbmd.DMDRelated_DCM_Phenotype"><h4><i>DMD-</i>Related DCM Phenotype</h4><p>Cardiomyopathy management is similar to the management of DMD- or BMD-associated cardiomyopathy.</p></div></div><div id="dbmd.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p><b>Cardiorespiratory</b></p><ul><li class="half_rhythm"><div>Evaluation by pulmonary and cardiac specialists before surgeries [<a class="bk_pop" href="#dbmd.REF.finder.2004.456">Finder et al 2004</a>]</div></li><li class="half_rhythm"><div>Administration of pneumococcal vaccine and annual influenza vaccination [<a class="bk_pop" href="#dbmd.REF.finder.2004.456">Finder et al 2004</a>]</div></li></ul><p><b>Nutritional.</b> Assessment if:</p><ul><li class="half_rhythm"><div>Planning to commence steroids [<a class="bk_pop" href="#dbmd.REF.davidson.2009.383">Davidson &#x00026; Truby 2009</a>]</div></li><li class="half_rhythm"><div>Dysphagia is present</div></li><li class="half_rhythm"><div>Patient is chronically constipated</div></li><li class="half_rhythm"><div>Major surgery has been planned</div></li><li class="half_rhythm"><div>Patient is malnourished</div></li></ul><p><b>Muscular</b></p><ul><li class="half_rhythm"><div>Physical therapy to promote mobility and prevent contractures</div></li><li class="half_rhythm"><div>Exercise</div><ul><li class="half_rhythm"><div>All ambulatory boys with DMD or those in early non-ambulatory phase should participate in regular gentle exercise to avoid contractures and disuse atrophy.</div></li><li class="half_rhythm"><div>Exercise can consist of a combination of swimming pool and recreation-based activities. Swimming can be continued in non-ambulatory patients under close supervision, if medically safe.</div></li><li class="half_rhythm"><div>If patients complain of muscle pain during or after exercise, the activity should be reduced and monitoring for myoglobinuria should be carried out. Myoglobinuria within 24 hours after exercise indicates overexertion leading to rhabdomyolysis.</div></li></ul></li></ul><p><b>Bone health.</b> Assessments [<a class="bk_pop" href="#dbmd.REF.bushby.2010b.177">Bushby et al 2010b</a>, <a class="bk_pop" href="#dbmd.REF.darras.2018">Darras 2018</a>]:</p><ul><li class="half_rhythm"><div>Blood</div><ul><li class="half_rhythm"><div>Measurement of serum concentrations of calcium and phosphorus, and activity of alkaline phosphatase</div></li><li class="half_rhythm"><div>25-hydroxyvitamin D (25-OHD) level in springtime or biannually</div></li><li class="half_rhythm"><div>Consideration of magnesium and parathyroid hormone levels</div></li></ul></li><li class="half_rhythm"><div>Urine (calcium, sodium, creatinine)</div></li><li class="half_rhythm"><div>Dual energy x-ray absorptiometry (DEXA) scanning</div><ul><li class="half_rhythm"><div>At baseline (age &#x02265;3 years) or at start of corticosteroid therapy</div></li><li class="half_rhythm"><div>Repeated annually in those at risk (history of fractures, chronic corticosteroid therapy) and those with DEXA Z score &#x0003c;-2</div></li></ul></li><li class="half_rhythm"><div>Spine radiograph</div><ul><li class="half_rhythm"><div>If back pain is present</div></li><li class="half_rhythm"><div>To exclude vertebral compression fracture</div></li><li class="half_rhythm"><div>To assess degree of kyphoscoliosis if present on physical examination</div></li></ul></li><li class="half_rhythm"><div>Bone age if growth failure occurs (height for age &#x0003c;5th percentile or if linear growth is faltering) in persons on or off corticosteroids</div></li></ul><p>Interventions:</p><ul><li class="half_rhythm"><div>Exposure to sunshine and a balanced diet rich in vitamin D and calcium to improve bone density and reduce the risk of fractures. Supplementation should be carried out in consultation with a dietician.</div></li><li class="half_rhythm"><div>Vitamin D supplementation should be initiated if the vitamin D serum concentration is &#x0003c;20 ng/mL [<a class="bk_pop" href="#dbmd.REF.bachrach.2005.86">Bachrach 2005</a>, <a class="bk_pop" href="#dbmd.REF.biggar.2005.80">Biggar et al 2005</a>, <a class="bk_pop" href="#dbmd.REF.quinlivan.2005.72">Quinlivan et al 2005</a>] and should be considered in all children if levels cannot be maintained [<a class="bk_pop" href="#dbmd.REF.bushby.2010b.177">Bushby et al 2010b</a>]. Supplementation should be carried out in consultation with an endocrinologist and in accordance with country-specific pediatric guidelines.</div></li><li class="half_rhythm"><div>Intravenous bisphosphonates; recommended in persons with symptomatic vertebral fracture(s). A bone health expert should be consulted.</div></li><li class="half_rhythm"><div>Note: Use of oral biphosphonates for prophylaxis or treatment remains controversial.</div></li></ul></div><div id="dbmd.Surveillance"><h3>Surveillance</h3><div id="dbmd.Cardiac"><h4>Cardiac</h4><p>The American Academy of Pediatrics (AAP) has published recommendations for optimal cardiac care in persons with dystrophinopathy [<a class="bk_pop" href="#dbmd.REF1">American Academy of Pediatrics Section on Cardiology and Cardiac Surgery 2005</a>] (<a href="http://pediatrics.aappublications.org/content/116/6/1569.long" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>) and consensus guidelines [<a class="bk_pop" href="#dbmd.REF.bushby.2010b.177">Bushby et al 2010b</a>].</p><p><b>DMD</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Complete cardiac evaluation at least every two years, beginning at the time of diagnosis</div><div class="half_rhythm">Note: At minimum, the evaluation should include an electrocardiogram and a noninvasive cardiac imaging study such as echocardiography or cardiac MRI.</div></li><li class="half_rhythm"><div class="half_rhythm">At approximately age ten years, or at the onset of cardiac signs and symptoms, annual complete cardiac evaluation</div><div class="half_rhythm">Note: Most individuals with DMD demonstrating cardiac signs and symptoms are relatively late in their course.</div></li><li class="half_rhythm"><div class="half_rhythm">If evaluation reveals ventricular dysfunction, initiation of pharmacologic therapy and surveillance at least every six months [<a class="bk_pop" href="#dbmd.REF.bushby.2010a.77">Bushby et al 2010a</a>]</div></li></ul><p><b>BMD.</b> Complete cardiac evaluation at least every two years, beginning at the time of diagnosis. Evaluations should continue at least every two years.</p><p><b><i>DMD</i>-related DCM.</b> There are no consensus guidelines regarding the optimal cardiac care of patients with <i>DMD</i>-related DCM. However, once the diagnosis of DCM is made, patients will need complete cardiac evaluations at intervals defined by experienced cardiac specialists.</p><p><b>Asymptomatic females.</b> The AAP recommendations for optimal cardiac care of asymptomatic females with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#dbmd.REF1">American Academy of Pediatrics Section on Cardiology and Cardiac Surgery 2005</a>] include the following:</p><ul><li class="half_rhythm"><div>Education about the risk of developing cardiomyopathy and about the signs and symptoms of heart failure</div></li><li class="half_rhythm"><div>Complete cardiac evaluation by a cardiac specialist with experience in the treatment of heart failure and/or neuromuscular disorders, with the initial evaluation to take place in late adolescence or early adulthood, or earlier at the appearance of cardiac signs and symptoms</div></li><li class="half_rhythm"><div>Starting at age 25 to 30 years, screening with a complete cardiac evaluation at least every five years</div></li><li class="half_rhythm"><div>Treatment of cardiac disease similar to that for boys with dystrophinopathy</div></li></ul></div><div id="dbmd.Pulmonary"><h4>Pulmonary</h4><p>Perform baseline pulmonary function testing before confinement to a wheelchair (usually age ~9-10 years)</p><p>Twice-yearly evaluation by a pediatric pulmonologist is indicated after ANY of the following [<a class="bk_pop" href="#dbmd.REF.finder.2004.456">Finder et al 2004</a>]:</p><ul><li class="half_rhythm"><div>Confinement to a wheelchair</div></li><li class="half_rhythm"><div>Reduction in vital capacity below 80% predicted</div></li><li class="half_rhythm"><div>Age 12 years</div></li></ul><p>The 2010 consensus guidelines [<a class="bk_pop" href="#dbmd.REF.bushby.2010b.177">Bushby et al 2010b</a>] make detailed recommendations regarding pulmonary care, including:</p><ul><li class="half_rhythm"><div>Use of self-inflating manual ventilation bag or mechanical insufflation-exsufflation device;</div></li><li class="half_rhythm"><div>Manual and mechanically assisted cough techniques;</div></li><li class="half_rhythm"><div>Indications for nocturnal and then daytime noninvasive ventilation as well as for tracheostomy.</div></li></ul></div><div id="dbmd.Orthopedic"><h4>Orthopedic</h4><p>Monitor for orthopedic complications, especially contractures and scoliosis in those with DMD and BMD phenotypes.</p><p>Evaluate for surgical interventions as needed.</p></div></div><div id="dbmd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Individuals with dystrophinopathy should avoid botulinum toxin injections.</p><p>Although it is recommended that triggering agents like succinylcholine and inhalational anesthetics be avoided in patients with dystrophinopathy because of susceptibility to malignant hyperthermia or malignant hyperthermia-like reactions (rhabdomyolysis, cardiac complications, hyperkalemia), it should be noted that an extensive literature search did not find an increased risk for malignant hyperthermia susceptibility in individuals with dystrophinopathy when compared with the general population [<a class="bk_pop" href="#dbmd.REF.gurnaney.2009.1043">Gurnaney et al 2009</a>]. However, individuals with DMD have been reported to have severe reactions to anesthesia (malignant hyperthermia-like) that did not meet the criteria for true malignant hyperthermia [<a class="bk_pop" href="#dbmd.REF.bamaga.2016.201">Bamaga et al 2016</a>].</p></div><div id="dbmd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk female family members (i.e., the sisters or maternal female relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male and first-degree relatives of a known or possible <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female) in order to identify as early as possible heterozygous females who would benefit from cardiac surveillance (see <a href="#dbmd.Surveillance">Surveillance</a>).</p><p>Evaluations can include the following:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known</div></li><li class="half_rhythm"><div>Serum CK testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known. Although serum CK concentration can be normal in <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> females, if elevated, it will support heterozygosity status in a female relative.</div></li><li class="half_rhythm"><div>Molecular genetic testing of the at-risk female if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing:</div><ul><li class="half_rhythm"><div>By <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> first</div></li><li class="half_rhythm"><div>If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a></div></li></ul></li><li class="half_rhythm"><div>Linkage analysis to determine <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status in at-risk females if (1) the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is not known, (2) no <i>DMD</i> pathogenic variant or serum CK elevation is identified in a carrier female, and (3) the family has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male with the unequivocal diagnosis of DMD/BMD/<i>DMD</i>-associated DCM</div><ul><li class="half_rhythm"><div class="half_rhythm">Linkage studies are based on accurate clinical diagnosis of DMD/BMD/<i>DMD</i>-associated DCM in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members and accurate understanding of the genetic relationships in the family.</div></li><li class="half_rhythm"><div class="half_rhythm">Linkage analysis relies on the availability and willingness of family members to be tested.</div></li><li class="half_rhythm"><div class="half_rhythm">Because the markers used for linkage in DMD/BMD/<i>DMD</i>-associated DCM are highly informative and lie both within and flanking the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>, they can be used in most families with DMD/BMD/<i>DMD</i>-associated DCM [<a class="bk_pop" href="#dbmd.REF.kim.2002.385">Kim et al 2002</a>].</div><div class="half_rhythm">Note: (1) The large size of <i>DMD</i> leads to an appreciable risk of <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a>. It has been estimated that the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> itself spans a genetic distance of 12 centimorgans [<a class="bk_pop" href="#dbmd.REF.abbs.1990.602">Abbs et al 1990</a>]; thus, multiple recombination events among different members of a family may complicate the interpretation of a linkage study. (2)Testing by linkage analysis is not possible for families in which there is a single <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male. (3) Testing by linkage analysis may not be widely available on a clinical basis.</div></li></ul></li></ul><p>See <a href="#dbmd.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="dbmd.Pregnancy_Management_for_Heterozygo"><h3>Pregnancy Management for Heterozygous Females</h3><p>Symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women should undergo an evaluation for dilated cardiomyopathy ideally prior to conceiving a pregnancy or as soon as the pregnancy is recognized. Asymptomatic heterozygous women should consider undergoing a cardiac evaluation prior to conception or when a pregnancy is recognized. Those with evidence of dilated cardiomyopathy should be treated and/or monitored by a cardiologist and a high-risk obstetrician.</p></div><div id="dbmd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>Gene therapy.</b> Clinical studies in <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> currently focus on restoring dystrophin expression by administering recombinant adeno-associated virus vectors that deliver either functional dystrophin transgene (micro- or minidystrophin genes) [<a class="bk_pop" href="#dbmd.REF.mendell.2010.1429">Mendell et al 2010</a>, <a class="bk_pop" href="#dbmd.REF.konieczny.2013.649">Konieczny et al 2013</a>, <a class="bk_pop" href="#dbmd.REF.bengtsson.2016.r9">Bengtsson et al 2016</a>] or gene-editing components [<a class="bk_pop" href="#dbmd.REF.calos.2016.1684">Calos 2016</a>, <a class="bk_pop" href="#dbmd.REF.long.2016.400">Long et al 2016</a>, <a class="bk_pop" href="#dbmd.REF.nelson.2016.403">Nelson et al 2016</a>, <a class="bk_pop" href="#dbmd.REF.tabebordbar.2016.407">Tabebordbar et al 2016</a>].</p><p><b>Gene repair.</b> CRISPR (clustered regularly interspaced short palindromic repeats)-associated protein 9 (CRISPR/Cas9)-mediated genome editing in <i>mdx</i> mice has been shown to partially restore dystrophin protein expression in cardiac and skeletal muscle by cutting the noncoding introns that flank the mutated sequence-containing <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 23 [<a class="bk_pop" href="#dbmd.REF.long.2016.400">Long et al 2016</a>, <a class="bk_pop" href="#dbmd.REF.nelson.2016.403">Nelson et al 2016</a>, <a class="bk_pop" href="#dbmd.REF.tabebordbar.2016.407">Tabebordbar et al 2016</a>].</p><p><b>Eteplirsen.</b> Another investigational approach uses antisense oligonucleotides, such as eteplirsen, to induce specific <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping during pre-messenger RNA <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, correcting the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> and restoring dystrophin expression [<a class="bk_pop" href="#dbmd.REF.goemans.2011.1513">Goemans et al 2011</a>, <a class="bk_pop" href="#dbmd.REF.lu.2011.9">Lu et al 2011</a>, <a class="bk_pop" href="#dbmd.REF.konieczny.2013.649">Konieczny et al 2013</a>, <a class="bk_pop" href="#dbmd.REF.jacobson.2016.259">Jacobson &#x00026; Feldman 2016</a>].</p><p>Eteplirsen skips <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 51, inducing a dose-related increase in dystrophin production without drug-related adverse effects [<a class="bk_pop" href="#dbmd.REF.cirak.2011.595">Cirak et al 2011</a>]. Affected individuals taking eteplirsen at a dose of 50 mg/kg showed a 23% increase in dystrophin-positive fibers at 24 weeks and walked a significantly greater distance in the six-minute walk test compared with placebo or delayed-administration groups at 48 weeks [<a class="bk_pop" href="#dbmd.REF.mendell.2013.637">Mendell et al 2013</a>]. At 36 months, those treated with eteplirsen had continued benefit on the six-minute walk test and a lower rate of loss of ambulation [<a class="bk_pop" href="#dbmd.REF.mendell.2016.257">Mendell et al 2016</a>].</p><p>The FDA granted accelerated approval for eteplirsen infusion in September 2016, making it the first drug approved to treat individuals with DMD; however, the manufacturer is required to conduct a trial to determine whether eteplirsen improves motor function of individuals with DMD with an amenable dystrophin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FDA news release</a>). The FDA may withdraw approval if this trial fails to show clinical benefit.</p><p><b>Ataluren.</b> Ten to 15 percent of individuals with DMD harbor <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> (stop) pathogenic variants, which the investigational drug ataluren may treat by promoting ribosomal read-through, allowing bypass of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and continuation of the translation process to production of a functioning protein [<a class="bk_pop" href="#dbmd.REF.finkel.2010.1158">Finkel 2010</a>].</p><p>Preclinical efficacy studies showed production of dystrophin in primary muscle cells from humans and <i>mdx</i> mice [<a class="bk_pop" href="#dbmd.REF.welch.2007.87">Welch et al 2007</a>]. Studies in humans have shown increased full-length dystrophin expression in vitro and in vivo, and decreased serum muscle enzyme levels within 28 days of treatment [<a class="bk_pop" href="#dbmd.REF.b_nnemann.2007.783">B&#x000f6;nnemann et al 2007</a>]. Affected individuals on low doses of ataluren had a 30-meter lower decline in the six-minute walk distance than those on high doses or placebo [<a class="bk_pop" href="#dbmd.REF.bushby.2014.477">Bushby et al 2014</a>]. Based on these results, the drug Translarna<sup>TM</sup> was granted conditional approval from the European Medicines Agency in August 2014 to treat DMD caused by a <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant; Translarna<sup>TM</sup> is not approved for treating DMD in the US.</p><p>A Phase III multicenter 48-week double-blind placebo-controlled trial (ACT DMD) showed no significant benefit of ataluren for the primary endpoint (i.e., change from baseline in the 6-minute walk test), though there was benefit for some secondary endpoints [<a class="bk_pop" href="#dbmd.REF.mcdonald.2017.1489">McDonald et al 2017</a>].</p><p><b>Myostatin inactivation.</b> The protein myostatin has an inhibitory effect on muscle growth; without it, mice that would otherwise express the DMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have increased muscle mass compared with those with a wild type myostatin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#dbmd.REF.wagner.2002.832">Wagner et al 2002</a>]. Animals treated with antibodies to myostatin have increased muscle mass and strength, lower serum creatine kinase, and less histologic evidence of muscle damage [<a class="bk_pop" href="#dbmd.REF.bogdanovich.2002.418">Bogdanovich et al 2002</a>], suggesting a potential therapeutic target to increase muscle bulk and strength in humans with DMD [<a class="bk_pop" href="#dbmd.REF.mcnally.2004.2642">McNally 2004</a>].</p><p><a class="bk_pop" href="#dbmd.REF.wagner.2008.561">Wagner et al [2008]</a> conducted a double-blind placebo-controlled multinational randomized study of 116 subjects to test the safety of a neutralizing antibody to myostatin, MYO-029. <a class="bk_pop" href="#dbmd.REF.campbell.2017.458">Campbell et al [2017]</a> found that ACE-031, a fusion protein that binds myostatin and related ligands, noted a trend toward maintenance of the six-minute walk test compared with a decline in the placebo group (not statistically significant), as well as a trend toward increased lean body mass and bone mineral density and reduced fat mass; however, the study was stopped due to non-muscle-related adverse effects.</p><p><b>Cell therapy.</b> Skeletal muscle progenitors continue to be investigated in the treatment of DMD. A promising technique in mice isolates and transplants muscle satellite cells, a natural source of cells for muscle regeneration [<a class="bk_pop" href="#dbmd.REF.blau.2008.1403">Blau 2008</a>, <a class="bk_pop" href="#dbmd.REF.cerletti.2008.37">Cerletti et al 2008</a>].</p><p><b>Idebenone.</b> A randomized controlled trial of the antioxidant idebenone showed significantly reduced decline in respiratory function as measured by peak expiratory flow and other pulmonary function tests [<a class="bk_pop" href="#dbmd.REF.buyse.2015.1748">Buyse et al 2015</a>]. Nearly all of the 64 individuals with DMD (age 10-18 years) were nonambulatory at baseline. Further study is needed to determine if idebenone treatment improves outcomes such as the time to assisted ventilation or to death.</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="dbmd.Genetic_Counseling"><h2 id="_dbmd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="dbmd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>The dystrophinopathies are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="dbmd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a>.</div></li><li class="half_rhythm"><div>If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child and no other affected relatives and if the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. The likelihood of germline mosaicism for a <i>DMD</i> pathogenic variant in this instance is 15%-20% (empiric risk). Consequently, each of her offspring is at increased risk of inheriting the DMD pathogenic variant [<a class="bk_pop" href="#dbmd.REF.van_essen.1992.258">van Essen et al 1992</a>, <a class="bk_pop" href="#dbmd.REF.van_essen.2003.296">van Essen et al 2003</a>, <a class="bk_pop" href="#dbmd.REF.wang.2017.356">Wang et al 2017</a>].</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> or the affected male may have a <i>de novo DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a heterozygote. Approximately two thirds of mothers of males with DMD and no family history of DMD are heterozygotes.</div></li><li class="half_rhythm"><div>Recommendations for the mother of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>; <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females need to be identified for the purpose of cardiac surveillance (see <a href="#dbmd.Surveillance">Surveillance</a>).</div></li><li class="half_rhythm"><div>Molecular genetic testing can be used to determine the point of origin of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. This information is important for determining which branches of the family are at risk for the dystrophinopathies.</div></li><li class="half_rhythm"><div>Rarely, a female may be the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. A female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from either her mother or her father or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>. Molecular genetic testing of the mother (and possibly &#x02013; or subsequently &#x02013; the father) is recommended.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the mother; if the proband is female, the risk to sibs depends the genetic status of the mother and the father.</div></li><li class="half_rhythm"><div>If the mother of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and may have a range of clinical manifestations (see <a href="#dbmd.Clinical_Description">Clinical Description</a>).</div></li><li class="half_rhythm"><div>If the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is not detectable in maternal leukocyte DNA, it is possible that the proband has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant. However, because the likelihood of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in this instance is 15%-20%, the sibs of a proband are at increased risk of inheriting the family-specific <i>DMD</i> pathogenic variant.</div></li><li class="half_rhythm"><div>If the mother has concomitant somatic and <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>, the risk to sibs of inheriting the family-specific <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may be higher than if the mother has germline mosaicism only [<a class="bk_pop" href="#dbmd.REF.van_essen.2003.296">van Essen et al 2003</a>].</div></li><li class="half_rhythm"><div>If the father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> female has a <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, he will transmit it to all of his daughters and none of his sons.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Males with DMD usually die before reproductive age or are too debilitated to reproduce. If they were to reproduce, all male offspring would be unaffected and all female offspring would be heterozygotes and could have a range of clinical manifestations (see <a href="#dbmd.Clinical_Description">Clinical Description</a>).</div></li><li class="half_rhythm"><div>Males with BMD and <i>DMD</i>-associated DCM may reproduce. All of the daughters will be heterozygotes. None of the sons will inherit their father's <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Women with a <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of transmitting the pathogenic variant to each child.</div></li></ul><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal grandmother, maternal aunts, and their offspring may be at risk of being heterozygotes or being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (depending on their gender, family relationship, and the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of the proband's mother).</p></div><div id="dbmd.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Carrier testing is possible for at-risk females. See Management, <a href="#dbmd.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>.</p><p>Females who are identified as <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> need to be informed of their risk for <i>DMD</i>-associated cardiomyopathy, as well as the recommended surveillance.</p></div><div id="dbmd.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#dbmd.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>BMD and <i>DMD</i>-associated DCM are sometimes observed in the same family [<a class="bk_pop" href="#dbmd.REF.palmucci.2000.529">Palmucci et al 2000</a>]. Thus, the entire spectrum of possible muscle disease should be considered when obtaining a family history and providing <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="dbmd.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for a dystrophinopathy are possible.</p><p><b>Fetal muscle biopsy.</b> In utero fetal muscle biopsy has been used in the <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of DMD in families with DMD in which the <i>DMD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not known [<a class="bk_pop" href="#dbmd.REF.ladwig.2002.79">Ladwig et al 2002</a>].</p><p>The history of molecular diagnostic testing in DMD and the impact of new techniques including <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> microarray (CMA) analysis and noninvasive <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> methods are reviewed in various publications [<a class="bk_pop" href="#dbmd.REF.raymond.2010.674">Raymond et al 2010</a>, <a class="bk_pop" href="#dbmd.REF.xu.2015.889">Xu et al 2015</a>, <a class="bk_pop" href="#dbmd.REF.parks.2016.312">Parks et al 2016</a>].</p></div></div><div id="dbmd.Resources"><h2 id="_dbmd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Duchenne%20/%20Becker%20Muscular%20Dystrophy&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Duchenne / Becker Muscular Dystrophy</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=musculardystrophyduchenneandbeckertypes" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Muscular dystrophy, Duchenne and Becker types</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22263/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Duchenne muscular dystrophy</a></div></li><li class="half_rhythm"><div><b>Parent Project Muscular Dystrophy</b></div><div>158 Linwood Plaza</div><div>Suite 220</div><div>Fort Lee NJ 07024</div><div><b>Phone:</b> 800-714-5437 (toll-free); 201-944-9985</div><div><b>Fax:</b> 201-944-9987</div><div><b>Email:</b> info@parentprojectmd.org</div><div><a href="http://www.parentprojectmd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.parentprojectmd.org</a></div></li><li class="half_rhythm"><div><b>European Neuromuscular Centre (ENMC)</b></div><div>Lt Gen van Heutszlaan 6</div><div>3743 JN Baarn</div><div>Netherlands</div><div><b>Phone:</b> 31 35 5480481</div><div><b>Fax:</b> 31 35 5480499</div><div><b>Email:</b> enmc@enmc.org</div><div><a href="http://www.enmc.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.enmc.org</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/musculardystrophy.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Muscular Dystrophy</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - Canada</b></div><div>2345 Yonge Street</div><div>Suite 900</div><div>Toronto Ontario M4P 2E5</div><div>Canada</div><div><b>Phone:</b> 866-687-2538 (toll-free); 416-488-0030</div><div><b>Fax:</b> 416-488-7523</div><div><b>Email:</b> info@muscle.ca</div><div><a href="http://www.muscle.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.muscle.ca</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy UK</b></div><div>61A Great Suffolk Street</div><div>London SE1 0BU </div><div>United Kingdom</div><div><b>Phone:</b> 0800 652 6352 (toll-free); 020 7803 4800</div><div><b>Email:</b> info@musculardystrophyuk.org</div><div><a href="http://www.musculardystrophyuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.musculardystrophyuk.org</a></div></li><li class="half_rhythm"><div><b>DuchenneConnect Patient Registry</b></div><div><i>DuchenneConnect has been created to serve as a central hub linking the resources and needs of the Duchenne/Becker MD community. One goal of their Registry is to develop new and improved treatments and learn more about the impact of Duchenne/Becker muscular dystrophy on individuals and families.</i></div><div>c/o The Parent Project for Muscular Dystrophy Research, Inc.</div><div>401 Hackensack Avenue</div><div>9th Floor</div><div>Hackensack NJ 07601</div><div><b>Phone:</b> 404-778-0553</div><div><b>Fax:</b> 404-935-0636</div><div><b>Email:</b> coordinator@duchenneconnect.org</div><div><a href="http://www.duchenneconnect.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.duchenneconnect.org</a></div></li></ul></div><div id="dbmd.Molecular_Genetics"><h2 id="_dbmd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="dbmd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Dystrophinopathies: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_dbmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_dbmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_dbmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_dbmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_dbmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_dbmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_dbmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1756" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>DMD</i></a></td><td headers="hd_b_dbmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1756" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp21<wbr style="display:inline-block"></wbr>​.2-p21.1</a></td><td headers="hd_b_dbmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P11532" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dystrophin</a></td><td headers="hd_b_dbmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/DMD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DMD homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_dbmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=DMD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DMD</a></td><td headers="hd_b_dbmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=DMD[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DMD</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="dbmd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="dbmd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Dystrophinopathies (<a href="/omim/300376,300377,302045,310200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1119/table/dbmd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dbmd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300376" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300376</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCULAR DYSTROPHY, BECKER TYPE; BMD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300377" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300377</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DYSTROPHIN; DMD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/302045" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">302045</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CARDIOMYOPATHY, DILATED, 3B; CMD3B</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/310200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">310200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>DMD</i> spans 2.2 Mb of DNA and comprises 79 exons. It has at least four promoters. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1119/#dbmd.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Innumerable intragenic variants have been described, many of which have been used clinically for genetic linkage analysis.</p><p><b>Pathogenic variants.</b> More than 5,000 pathogenic variants have been identified in persons with DMD or BMD [<a class="bk_pop" href="#dbmd.REF.aartsmarus.2006.135">Aartsma-Rus et al 2006</a>, <a class="bk_pop" href="#dbmd.REF.flanigan.2009.1657">Flanigan et al 2009</a>, <a class="bk_pop" href="#dbmd.REF.tufferygiraud.2009.934">Tuffery-Giraud et al 2009</a>]. Disease-causing alleles are highly variable, including <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, deletion or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of one or more exons, and small deletions, insertions, or single-base changes. In both DMD and BMD, partial deletions and duplications cluster in two <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> hot spots, one proximal at the 5' end of the gene, comprising exons 2-20 (30%), and one more distal, comprising exons 44-53 (70%) [<a class="bk_pop" href="#dbmd.REF.den_dunnen.1989.835">Den Dunnen et al 1989</a>]. Duplications cluster near the 5' end of the gene, with duplication of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 being the single most common duplication identified [<a class="bk_pop" href="#dbmd.REF.white.2006.938">White et al 2006</a>].</p><p>The frequencies for types of pathogenic variants given in this section are for individuals with DMD or BMD. Data are insufficient to estimate the percentage of individuals with <i>DMD</i>-associated dilated cardiomyopathy with detectable <i>DMD</i> pathogenic variants.</p><p><b>Deletions of one or more exons</b> may result in <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> or out-of-frame transcripts and account for approximately 60%-70% of pathogenic variants in individuals with DMD and BMD [<a class="bk_pop" href="#dbmd.REF.yan.2004.203">Yan et al 2004</a>, <a class="bk_pop" href="#dbmd.REF.dent.2005.295">Dent et al 2005</a>, <a class="bk_pop" href="#dbmd.REF.prior.2005.317">Prior &#x00026; Bridgeman 2005</a>, <a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>].</p><p><b>Duplications</b> may result in <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> or out-of-frame transcripts and account for approximately 5%-10% of pathogenic variants in males with DMD and BMD [<a class="bk_pop" href="#dbmd.REF.white.2002.365">White et al 2002</a>, <a class="bk_pop" href="#dbmd.REF.white.2006.938">White et al 2006</a>, <a class="bk_pop" href="#dbmd.REF.flanigan.2009.1657">Flanigan et al 2009</a>, <a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>]. Duplications may be slightly more common in BMD: one small series found duplications in 14 (19%) of 75 males with BMD [<a class="bk_pop" href="#dbmd.REF.kesari.2008.728">Kesari et al 2008</a>]; however, most studies, including those using newer techniques such as MLPA, have not found rates higher than 10% in BMD [<a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>].</p><p><b>Single-nucleotide variants (SNVs), small deletions or insertions, single-base changes, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> changes</b> account for approximately 25%-35% of pathogenic variants in males with DMD and about 10%-20% of males with BMD [<a class="bk_pop" href="#dbmd.REF.bennett.2001.17">Bennett et al 2001</a>, <a class="bk_pop" href="#dbmd.REF.mendell.2001.645">Mendell et al 2001</a>, <a class="bk_pop" href="#dbmd.REF.dolinsky.2002.845">Dolinsky et al 2002</a>, <a class="bk_pop" href="#dbmd.REF.flanigan.2003.931">Flanigan et al 2003</a>, <a class="bk_pop" href="#dbmd.REF.hofstra.2004.57">Hofstra et al 2004</a>, <a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>].</p><ul><li class="half_rhythm"><div>Nonsense variants occur more commonly in DMD &#x02013; in the range of 20%-25% of cases &#x02013; as compared to fewer than 5% in BMD [<a class="bk_pop" href="#dbmd.REF.flanigan.2009.1657">Flanigan et al 2009</a>, <a class="bk_pop" href="#dbmd.REF.takeshima.2010.379">Takeshima et al 2010</a>].</div></li><li class="half_rhythm"><div>Splice site variants and small insertions/deletions (indels) are a substantial proportion of sequence changes in both DMD and BMD.</div></li><li class="half_rhythm"><div>Missense variants are not a common cause of either Duchenne or Becker dystrophy.</div></li></ul><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Dystrophin is a membrane-associated protein present in muscle cells and some neurons. The N-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> binds to actin. A large rod domain includes 24 homologous repeats forming an &#x003b1;-helical structure, a cysteine-rich calcium-binding region near the C terminus, and a C-terminal domain that binds with other membrane proteins. Dystrophin is therefore part of a protein complex that links the cytoskeleton with membrane proteins that in turn bind with proteins in the extracellular matrix.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants that lead to lack of dystrophin expression tend to cause DMD, whereas those that lead to abnormal quality or quantity of dystrophin lead to BMD. In <i>DMD</i>-associated DCM, functional dystrophin is absent in the myocardium but may be normal or mildly abnormal in skeletal muscle [<a class="bk_pop" href="#dbmd.REF.ferlini.1999.339">Ferlini et al 1999</a>, <a class="bk_pop" href="#dbmd.REF.neri.2007.913">Neri et al 2007</a>] because <i>DMD</i>-associated DCM is associated with specific types of <i>DMD</i> pathogenic variants that have a differential response to tissue-specific transcription or alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> in cardiac vs skeletal muscle.</p></div><div id="dbmd.References"><h2 id="_dbmd_References_">References</h2><div id="dbmd.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF1">American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Clinical Report: cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Available <a href="http://pediatrics.aappublications.org/content/116/6/1569.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2005. Accessed 1-14-19. [<a href="/pubmed/16322188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16322188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bushby.2010">Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Available <a href="https://www.sciencedirect.com/science/article/pii/S1474442209702728?via%3Dihub" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010 Accessed 1-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.moxley.2005">Moxley RT III, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Available <a href="http://www.neurology.org/content/64/1/13.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2005. Accessed 1-14-19. [<a href="/pubmed/15642897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15642897</span></a>]</div></li></ul></div><div id="dbmd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.aartsmarus.2006.135">Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. <span><span class="ref-journal">Muscle Nerve. </span>2006;<span class="ref-vol">34</span>:135–44.</span> [<a href="/pubmed/16770791" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16770791</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.abbs.1990.602">Abbs S, Roberts RG, Mathew CG, Bentley DR, Bobrow M. Accurate assessment of intragenic recombination frequency within the Duchenne muscular dystrophy gene. <span><span class="ref-journal">Genomics. </span>1990;<span class="ref-vol">7</span>:602–6.</span> [<a href="/pubmed/1974880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1974880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.allen.2013">Allen HD, Flanigan KM, Thrush PT, Dvorchik I, Yin H, Canter C, Connolly AM, Parrish M, McDonald CM, Braunlin E, Colan SD, Day J, Darras B, Mendell JR (2013) A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy. PLoS Curr. Dec 12;5. [<a href="/pmc/articles/PMC3871420/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3871420</span></a>] [<a href="/pubmed/24459612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24459612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.american_academy_of_pediatrics_section_on_cardiology_and_cardiac_surgery.2005.1569">American Academy of Pediatrics Section on Cardiology and Cardiac Surgery.  Clinical Report: cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. <span><span class="ref-journal">Pediatrics. </span>2005;<span class="ref-vol">116</span>:1569–73.</span> [<a href="/pubmed/16322188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16322188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bachrach.2005.86">Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:86–7.</span> [<a href="/pubmed/15639126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15639126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bamaga.2016.201">Bamaga AK, Riazi S, Amburgey K, Ong S, Halliday W, Diamandis P, Guerguerian AM, Dowling JJ, Yoon G. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: a 25-year retrospective study. <span><span class="ref-journal">Neuromuscul Disord. </span>2016;<span class="ref-vol">26</span>:201–6.</span> [<a href="/pubmed/26951757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26951757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.banihani.2015.1472">Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A, McAdam L. Cognitive and neurobehavioral profile in boys with Duchenne muscular dystrophy. <span><span class="ref-journal">J Child Neurol. </span>2015;<span class="ref-vol">30</span>:1472–82.</span> [<a href="/pubmed/25660133" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25660133</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.battini.2018.122">Battini R, Chieffo D, Bulgheroni S, Piccini G, Pecini C, Lucibello S, Lenzi S, Moriconi F, Pane M, Astrea G, Baranello G, Alfieri P, Vicari S, Riva D, Cioni G, Mercuri E. Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: the role of executive functions. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:122–8.</span> [<a href="/pubmed/29305139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29305139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.beggs.1997.2344">Beggs AH. Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. <span><span class="ref-journal">Circulation. </span>1997;<span class="ref-vol">95</span>:2344–7.</span> [editorial; comment] [<a href="/pubmed/9170393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9170393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bengtsson.2016.r9">Bengtsson NE, Seto JT, Hall JK, Chamberlain JS, Odom GL. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. <span><span class="ref-journal">Hum Mol Genet. </span>2016;<span class="ref-vol">25</span>:R9–R17.</span> [<a href="/pmc/articles/PMC4802376/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4802376</span></a>] [<a href="/pubmed/26450518" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26450518</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bennett.2001.17">Bennett RR, den Dunnen J, O'Brien KF, Darras BT, Kunkel LM. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. <span><span class="ref-journal">BMC Genet. </span>2001;<span class="ref-vol">2</span>:17.</span> [<a href="/pmc/articles/PMC59832/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC59832</span></a>] [<a href="/pubmed/11710958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11710958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.biggar.2005.80">Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:80–5.</span> [<a href="/pubmed/15639125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15639125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.blau.2008.1403">Blau HM. Cell therapies for muscular dystrophy. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>:1403–5.</span> [<a href="/pubmed/18815403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18815403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bogdanovich.2002.418">Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. <span><span class="ref-journal">Nature. </span>2002;<span class="ref-vol">420</span>:418–21.</span> [<a href="/pubmed/12459784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12459784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.b_nnemann.2007.783">B&#x000f6;nnemann C, Finkel R, Wong B, Flanigan K, Sampson J, Sweeney L, Reha A, Elfring G, Miller L, Hirawat S. Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>2007;<span class="ref-vol">17</span>:783.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bushby.2010a.77">Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. <span><span class="ref-journal">Lancet Neurol. </span>2010a;<span class="ref-vol">9</span>:77–93.</span> [<a href="/pubmed/19945913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19945913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bushby.2010b.177">Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. <span><span class="ref-journal">Lancet Neurol. </span>2010b;<span class="ref-vol">9</span>:177–89.</span> [<a href="/pubmed/19945914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19945914</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bushby.2014.477">Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW, Mcdonald CM, et al.  Ataluren treatment of patients with nonsense mutation dystrophinopathy. <span><span class="ref-journal">Muscle Nerve. </span>2014;<span class="ref-vol">50</span>:477.</span> [<a href="/pmc/articles/PMC4241581/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4241581</span></a>] [<a href="/pubmed/25042182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25042182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bushby.1999.1875">Bushby KM. The limb-girdle muscular dystrophies&#x02014;multiple genes, multiple mechanisms. <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:1875–82.</span> [<a href="/pubmed/10469840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10469840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.bushby.1991.1022">Bushby KM, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. <span><span class="ref-journal">Lancet. </span>1991;<span class="ref-vol">337</span>:1022–4.</span> [<a href="/pubmed/1673177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1673177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.buyse.2015.1748">Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T., DELOS Study Group.  Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. <span><span class="ref-journal">Lancet. </span>2015;<span class="ref-vol">385</span>:1748.</span> [<a href="/pubmed/25907158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25907158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.calos.2016.1684">Calos MP. The CRISPR way to think about Duchenne's. <span><span class="ref-journal">N Engl J Med. </span>2016;<span class="ref-vol">374</span>:1684–6.</span> [<a href="/pubmed/27119241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27119241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.campbell.2017.458">Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. <span><span class="ref-journal">Muscle Nerve. </span>2017;<span class="ref-vol">55</span>:458–64.</span> [<a href="/pubmed/27462804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27462804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.cerletti.2008.37">Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL, Goodyear LJ, Wagers AJ. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. <span><span class="ref-journal">Cell. </span>2008;<span class="ref-vol">134</span>:37–47.</span> [<a href="/pmc/articles/PMC3665268/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3665268</span></a>] [<a href="/pubmed/18614009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18614009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.chamberlain.2015.439">Chamberlain RC, Smith EC, Campbell NJ. Novel rod domain duplication in dystrophin resulting in X-linked dilated cardiomyopathy. <span><span class="ref-journal">Pediatr Neurol. </span>2015;<span class="ref-vol">53</span>:439–41.</span> [<a href="/pubmed/26294044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26294044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.chelly.1990.1239">Chelly J, Gilgenkrantz H, Lambert M, Hamard G, Chafey P, Recan D, Katz P, de la Chapelle A, Koenig M, Ginjaar IB, et al.  Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. <span><span class="ref-journal">Cell. </span>1990;<span class="ref-vol">63</span>:1239–48.</span> [<a href="/pubmed/2261642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2261642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.cirak.2011.595">Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. <span><span class="ref-journal">Lancet. </span>2011;<span class="ref-vol">378</span>:595.</span> [<a href="/pmc/articles/PMC3156980/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3156980</span></a>] [<a href="/pubmed/21784508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21784508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.connuck.2008.998">Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, Wilkinson JD, Orav EJ, Cuniberti L, Salbert BA, Lipshultz SE., Pediatric Cardiomyopathy Registry Study Group.  Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. <span><span class="ref-journal">Am Heart J. </span>2008;<span class="ref-vol">155</span>:998–1005.</span> [<a href="/pmc/articles/PMC2729548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2729548</span></a>] [<a href="/pubmed/18513510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18513510</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.cox.1997.329">Cox GF, Kunkel LM. Dystrophies and heart disease. <span><span class="ref-journal">Curr Opin Cardiol. </span>1997;<span class="ref-vol">12</span>:329–43.</span> [<a href="/pubmed/9243091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9243091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.damico.2017.447">D'Amico A, Catteruccia M, Baranello G, Politano L, Govoni A, Previtali SC, Pane M, D'Angelo MG, Bruno C, Messina S, Ricci F, Pegoraro E, Pini A, Berardinelli A, Gorni K, Battini R, Vita G, Trucco F, Scutifero M, Petillo R, D'Ambrosio P, Ardissone A, Pasanisi B, Vita G, Mongini T, Moggio M, Comi GP, Mercuri E, Bertini E. Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: critical issues and areas for improvements. <span><span class="ref-journal">Neuromuscul Disord. </span>2017;<span class="ref-vol">27</span>:447–51.</span> [<a href="/pubmed/28262469" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28262469</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.daoud.2009.3779">Daoud F, Angeard N, Demerre B, Martie I, Benyaou R, Leturcq F, Cossee M, Deburgrave N, Saillour Y, Tuffery S, Urtizberea A, Toutain A, Echenne B, Frischman M, Mayer M, Desguerre I, Estournet B, Reveillere C, Penisson-Besnier I, Cuisset JM, Kaplan JC, Heron D, Rivier F, Chelly J. Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:3779–94.</span> [<a href="/pubmed/19602481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19602481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.darras.2018">Darras BT. Duchenne and Becker muscular dystrophy: management and prognosis. In: Patterson MC, Dashe JF, eds. UpToDate&#x000ae;. Philadelphia, PA: Wolters Kluwer Health; 2018.</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.darras.1988.126">Darras BT, Francke U. Myopathy in complex glycerol kinase deficiency patients is due to 3' deletions of the dystrophin gene. <span><span class="ref-journal">Am J Hum Genet. </span>1988;<span class="ref-vol">43</span>:126–30.</span> [<a href="/pmc/articles/PMC1715358/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715358</span></a>] [<a href="/pubmed/2840818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2840818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.darras.2015">Darras BT, Menache-Starobinski CC, Hinton V, Kunkel LM. Dystrophinopathies. In: Darras BT, Jones HR Jr, Ryan MM, De Vivo DC, eds. <em>Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach</em>. 2 ed. San Diego, CA: Academic Press; 2015: 551-92.</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.davidson.2009.383">Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. <span><span class="ref-journal">J Hum Nutr Diet. </span>2009;<span class="ref-vol">22</span>:383–93.</span> [<a href="/pubmed/19743977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19743977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.de_brouwer.2014.480">de Brouwer AP, Nabuurs SB, Verhaart IE, Oudakker AR, Hordijk R, Yntema HG, Hordijk-Hos JM, Voesenek K, de Vries BB, van Essen T, Chen W, Hu H, Chelly J, den Dunnen JT, Kalscheuer VM, Aartsma-Rus AM, Hamel BC, van Bokhoven H, Kleefstra T. A 3-base pair deletion, c.9711_9713del, in DMD results in intellectual disability without muscular dystrophy. <span><span class="ref-journal">Eur J Hum Genet. </span>2014;<span class="ref-vol">22</span>:480–5.</span> [<a href="/pmc/articles/PMC3953899/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3953899</span></a>] [<a href="/pubmed/23900271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23900271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.deburgrave.2007.183">Deburgrave N, Daoud F, Llense S, Barbot JC, Recan D, Peccate C, Burghes AH, Beroud C, Garcia L, Kaplan JC, Chelly J, Leturcq F. Pro. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:183–95.</span> [<a href="/pubmed/17041906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17041906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.den_dunnen.1989.835">Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB, Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van Ommen GJ. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. <span><span class="ref-journal">Am J Hum Genet. </span>1989;<span class="ref-vol">45</span>:835–47.</span> [<a href="/pmc/articles/PMC1683480/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1683480</span></a>] [<a href="/pubmed/2573997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2573997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.dent.2005.295">Dent KM, Dunn DM, von Niederhausern AC, Aoyagi AT, Kerr L, Bromberg MB, Hart KJ, Tuohy T, White S, den Dunnen JT, Weiss RB, Flanigan KM. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">134</span>:295–8.</span> [<a href="/pubmed/15723292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15723292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.dolinsky.2002.845">Dolinsky LC, de Moura-Neto RS, Falcao-Conceicao DN. DGGE analysis as a tool to identify point mutations, de novo mutations and carriers of the dystrophin gene. <span><span class="ref-journal">Neuromuscul Disord. </span>2002;<span class="ref-vol">12</span>:845–8.</span> [<a href="/pubmed/12398835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12398835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.dooley.2010a.177">Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: a 30-year population-based incidence study. <span><span class="ref-journal">Clin Pediatr (Phila). </span>2010a;<span class="ref-vol">49</span>:177–9.</span> [<a href="/pubmed/20080524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20080524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.dooley.2010b.173">Dooley JM, Gordon KE, MacSween JM. Impact of steroids on surgical experiences of patients with Duchenne muscular dystrophy. <span><span class="ref-journal">Pediatr Neurol. </span>2010b;<span class="ref-vol">43</span>:173–6.</span> [<a href="/pubmed/20691938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20691938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.eagle.2007.470">Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K. Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival. <span><span class="ref-journal">Neuromuscul Disord. </span>2007;<span class="ref-vol">17</span>:470–5.</span> [<a href="/pubmed/17490881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17490881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.felisari.2000.559">Felisari G, Martinelli Boneschi F, Bardoni A, Sironi M, Comi GP, Robotti M, Turconi AC, Lai M, Corrao G, Bresolin N. Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">55</span>:559–64.</span> [<a href="/pubmed/10953192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10953192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.ferlini.1999.339">Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. <span><span class="ref-journal">Neuromuscul Disord. </span>1999;<span class="ref-vol">9</span>:339–46.</span> [<a href="/pubmed/10407857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10407857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.finder.2004.456">Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C, Schroth M, Sharma G, Sievers L, Silvestri JM, Sterni L. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2004;<span class="ref-vol">170</span>:456–65.</span> [<a href="/pubmed/15302625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15302625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.finkel.2010.1158">Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). <span><span class="ref-journal">J Child Neurol. </span>2010;<span class="ref-vol">25</span>:1158.</span> [<a href="/pmc/articles/PMC3674569/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3674569</span></a>] [<a href="/pubmed/20519671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20519671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.finsterer.2003.1">Finsterer J, Stollberger C. The heart in human dystrophinopathies. <span><span class="ref-journal">Cardiology. </span>2003;<span class="ref-vol">99</span>:1–19.</span> [<a href="/pubmed/12589117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12589117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.flanigan.2009.1657">Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, Sampson JB, Mendell JR, Wall C, King WM, Pestronk A, Florence JM, Connolly AM, Mathews KD, Stephan CM, Laubenthal KS, Wong BL, Morehart PJ, Meyer A, Finkel RS, Bonnemann CG, Medne L, Day JW, Dalton JC, Margolis MK, Hinton VJ, Weiss RB, et al.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:1657–66.</span> [<a href="/pmc/articles/PMC3404892/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3404892</span></a>] [<a href="/pubmed/19937601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19937601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.flanigan.2003.931">Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">72</span>:931–9.</span> [<a href="/pmc/articles/PMC1180355/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180355</span></a>] [<a href="/pubmed/12632325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12632325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.francke.1985.250">Francke U, Ochs HD, de Martinville B, Giacalone J, Lindgren V, Disteche C, Pagon RA, Hofker MH, van Ommen GJ, Pearson PL, et al.  Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>1985;<span class="ref-vol">37</span>:250–67.</span> [<a href="/pmc/articles/PMC1684578/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1684578</span></a>] [<a href="/pubmed/4039107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4039107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.gavillet.2006.407">Gavillet B, Rougier JS, Domenighetti AA, Behar R, Boixel C, Ruchat P, Lehr HA, Pedrazzini T, Abriel H. Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. <span><span class="ref-journal">Circ Res. </span>2006;<span class="ref-vol">99</span>:407–14.</span> [<a href="/pubmed/16857961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16857961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.giliberto.2014.36">Giliberto F, Radic CP, Luce L, Ferreiro V, de Brasi C, Szijan I. Symptomatic female carriers of Duchenne muscular dystrophy (DMD): genetic and clinical characterization. <span><span class="ref-journal">J Neurol Sci. </span>2014;<span class="ref-vol">336</span>:36–41.</span> [<a href="/pubmed/24135430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24135430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.goemans.2011.1513">Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC. Systemic administration of PRO051 in Duchenne's muscular dystrophy. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:1513–22.</span> [<a href="/pubmed/21428760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21428760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.gurnaney.2009.1043">Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. <span><span class="ref-journal">Anesth Analg. </span>2009;<span class="ref-vol">109</span>:1043–8.</span> [<a href="/pubmed/19762730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19762730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hermans.2010.479">Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. <span><span class="ref-journal">Neuromuscul Disord. </span>2010;<span class="ref-vol">20</span>:479–92.</span> [<a href="/pubmed/20627570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20627570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hinton.2001.45">Hinton VJ, De Vivo DC, Nereo NE, Goldstein E, Stern Y. Selective deficits in verbal working memory associated with a known genetic etiology: the neuropsychological profile of duchenne muscular dystrophy. <span><span class="ref-journal">J Int Neuropsychol Soc. </span>2001;<span class="ref-vol">7</span>:45–54.</span> [<a href="/pmc/articles/PMC1931425/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1931425</span></a>] [<a href="/pubmed/11253841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11253841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hoffman.1988.1363">Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L, et al.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. <span><span class="ref-journal">N Engl J Med. </span>1988;<span class="ref-vol">318</span>:1363–8.</span> [<a href="/pubmed/3285207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3285207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hoffman.1991.605">Hoffman EP, Garcia CA, Chamberlain JS, Angelini C, Lupski JR, Fenwick R. Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>1991;<span class="ref-vol">30</span>:605–10.</span> [<a href="/pubmed/1789686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1789686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hofstra.2004.57">Hofstra RM, Mulder IM, Vossen R, de Koning-Gans PA, Kraak M, Ginjaar IB, van der Hout AH, Bakker E, Buys CH, van Ommen GJ, van Essen AJ, den Dunnen JT. DGGE-based whole-gene mutation scanning of the dystrophin gene in Duchenne and Becker muscular dystrophy patients. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:57–66.</span> [<a href="/pubmed/14695533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14695533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hoogerwaard.1999a.2116">Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, Van Essen AJ, Brunner HG, van der Wouw PA, Wilde AA, de Visser M. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. <span><span class="ref-journal">Lancet. </span>1999a;<span class="ref-vol">353</span>:2116–9.</span> [<a href="/pubmed/10382696" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10382696</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.hoogerwaard.1999b.347">Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, van Essen AJ, Leschot NJ, de Visser M. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>1999b;<span class="ref-vol">9</span>:347–51.</span> [<a href="/pubmed/10407858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10407858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.jacobson.2016.259">Jacobson RD, Feldman EL. Antisense oligonucleotides for Duchenne muscular dystrophy: why no neurologist should skip this. <span><span class="ref-journal">JAMA Neurol. </span>2016;<span class="ref-vol">73</span>:259–60.</span> [<a href="/pubmed/26746046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26746046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.jefferies.2005.2799">Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. <span><span class="ref-journal">Circulation. </span>2005;<span class="ref-vol">112</span>:2799–804.</span> [<a href="/pubmed/16246949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16246949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.juanmateu.2013.753">Juan-Mateu J, Gonz&#x000e1;lez-Quereda L, Rodriguez MJ, Jou C, Nascimento A, Jimenez-Mallebrera C, Colomer J, Baiget M, Olive M, Gallano P. Isolated cognitive abnormalities associated to DMD mutations. <span><span class="ref-journal">Neuromuscul Disord. </span>2013;<span class="ref-vol">23</span>:753.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.juanmateu.2012.82">Juan-Mateu J, Rodr&#x000ed;guez MJ, Nascimento A, Jim&#x000e9;nez-Mallebrera C, Gonz&#x000e1;lez-Quereda L, Rivas E, Paradas C, Madruga M, S&#x000e1;nchez-Ayaso P, Jou C, Gonz&#x000e1;lez-Mera L, Munell F, Roig-Quilis M, Rabasa M, Hern&#x000e1;ndez-Lain A, D&#x000ed;az-Manera J, Gallardo E, Pascual J, Verdura E, Colomer J, Baiget M, Oliv&#x000e9; M, Gallano P. Prognostic value of X-chromosome inactivation in symptomatic female carriers of dystrophinopathy. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:82.</span> [<a href="/pmc/articles/PMC3492175/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3492175</span></a>] [<a href="/pubmed/23092449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23092449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.kamdar.2016.2533">Kamdar F, Garry DJ. Dystrophin-deficient cardiomyopathy. <span><span class="ref-journal">J Am Coll Cardiol. </span>2016;<span class="ref-vol">67</span>:2533–46.</span> [<a href="/pubmed/27230049" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27230049</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.kaspar.2009.544">Kaspar RW, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, Weiss RB, Flanigan KM, Mendell JR, Montanaro F. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2009;<span class="ref-vol">2</span>:544–51.</span> [<a href="/pmc/articles/PMC2826810/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2826810</span></a>] [<a href="/pubmed/20031633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20031633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.kesari.2008.728">Kesari A, Pirra LN, Bremadesam L, McIntyre O, Gordon E, Dubrovsky AL, Viswanathan V, Hoffman EP. Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:728–37.</span> [<a href="/pubmed/18348289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18348289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.kim.2002.385">Kim UK, Chae JJ, Lee SH, Lee CC, Namkoong Y. Molecular diagnosis of Duchenne/Becker muscular dystrophy by polymerase chain reaction and microsatellite analysis. <span><span class="ref-journal">Mol Cells. </span>2002;<span class="ref-vol">13</span>:385–8.</span> [<a href="/pubmed/12132577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12132577</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.king.2007.1607">King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">68</span>:1607–13.</span> [<a href="/pubmed/17485648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17485648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.koenig.1989.498">Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M, Kaariainen H, et al.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. <span><span class="ref-journal">Am J Hum Genet. </span>1989;<span class="ref-vol">45</span>:498–506.</span> [<a href="/pmc/articles/PMC1683519/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1683519</span></a>] [<a href="/pubmed/2491009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2491009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.konieczny.2013.649">Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. <span><span class="ref-journal">Muscle Nerve. </span>2013;<span class="ref-vol">47</span>:649–63.</span> [<a href="/pmc/articles/PMC4077844/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4077844</span></a>] [<a href="/pubmed/23553671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23553671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.ladwig.2002.79">Ladwig D, Mowat D, Tobias V, Taylor PJ, Buckley MF, McNally G, Challis D. In utero fetal muscle biopsy in the diagnosis of Duchenne muscular dystrophy. <span><span class="ref-journal">Aust N Z J Obstet Gynaecol. </span>2002;<span class="ref-vol">42</span>:79–82.</span> [<a href="/pubmed/11926646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11926646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.li.2012.746">Li QX, Yang H, Zhang N, Xiao B, Bi FF, Li J. <span><span class="ref-journal">Zhongguo Dang Dai Er Ke Za Zhi. </span>2012;<span class="ref-vol">14</span>:746–50.</span> [Clinical and pathological features of 50 children with Duchenne's muscular dystrophy] [<a href="/pubmed/23092565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23092565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.liang.2018.176">Liang WC, Wang CH, Chou PC, Chen WZ, Jong YJ. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: a medical center experience. <span><span class="ref-journal">Pediatr Neonatol. </span>2018;<span class="ref-vol">59</span>:176–83.</span> [<a href="/pubmed/28903883" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28903883</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.lin.2009.476">Lin JJ, Hwang MS, Hsia SH, Chung HT, Chang YS, Lin KL. Pericardial effusion with cardiac tamponade as a cardiac manifestation of Duchenne muscular dystrophy. <span><span class="ref-journal">Muscle Nerve. </span>2009;<span class="ref-vol">40</span>:476–80.</span> [<a href="/pubmed/19623636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19623636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.long.2016.400">Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. <span><span class="ref-journal">Science. </span>2016;<span class="ref-vol">351</span>:400–3.</span> [<a href="/pmc/articles/PMC4760628/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4760628</span></a>] [<a href="/pubmed/26721683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26721683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.lu.2011.9">Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T. The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. <span><span class="ref-journal">Mol Ther. </span>2011;<span class="ref-vol">19</span>:9.</span> [<a href="/pmc/articles/PMC3017449/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3017449</span></a>] [<a href="/pubmed/20978473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20978473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mavrogeni.2010.33">Mavrogeni S, Papavasiliou A, Spargias K, Constandoulakis P, Papadopoulos G, Karanasios E, Georgakopoulos D, Kolovou G, Demerouti E, Polymeros S, Kaklamanis L, Magoutas A, Papadopoulou E, Markussis V, Cokkinos DV. Myocardial inflammation in Duchenne Muscular Dystrophy as a precipitating factor for heart failure: a prospective study. <span><span class="ref-journal">BMC Neurol. </span>2010;<span class="ref-vol">10</span>:33.</span> [<a href="/pmc/articles/PMC2885327/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2885327</span></a>] [<a href="/pubmed/20492678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20492678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mccaffrey.2017.810">Mccaffrey T, Guglieri M, Murphy AP, Bushby K, Johnson A, Bourke JP. Cardiac involvement in female carriers of Duchenne or Becker muscular dystrophy. <span><span class="ref-journal">Muscle Nerve. </span>2017;<span class="ref-vol">55</span>:810–8.</span> [<a href="/pubmed/27761893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27761893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mcdonald.2017.1489">McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E, et al.  Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <span><span class="ref-journal">Lancet. </span>2017;<span class="ref-vol">390</span>:1489.</span> [<a href="/pubmed/28728956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28728956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mcnally.2004.2642">McNally EM. Powerful genes--myostatin regulation of human muscle mass. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>:2642.</span> [<a href="/pubmed/15215479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15215479</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.melacini.1996.3168">Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, Freda MP, Miorelli M, Mostacciuolo ML, Fasoli G, Angelini C, Dalla Volta S. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. <span><span class="ref-journal">Circulation. </span>1996;<span class="ref-vol">94</span>:3168–75.</span> [<a href="/pubmed/8989125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8989125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mendell.2001.645">Mendell JR, Buzin CH, Feng J, Yan J, Serrano C, Sangani DS, Wall C, Prior TW, Sommer SS. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:645–50.</span> [<a href="/pubmed/11524473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11524473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mendell.2010.1429">Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM. Dystrophin immunity in Duchenne's muscular dystrophy. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:1429–37.</span> [<a href="/pmc/articles/PMC3014106/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3014106</span></a>] [<a href="/pubmed/20925545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20925545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mendell.2016.257">Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E., Eteplirsen Study Group and Telethon Foundation DMD Italian Network.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>2016;<span class="ref-vol">79</span>:257–71.</span> [<a href="/pmc/articles/PMC5064753/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5064753</span></a>] [<a href="/pubmed/26573217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26573217</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mendell.2013.637">Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM., Eteplirsen Study Group.  Eteplirsen for the treatment of Duchenne muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>2013;<span class="ref-vol">74</span>:637–47.</span> [<a href="/pubmed/23907995" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23907995</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mercier.2013.855">Mercier S, Toutain A, Toussaint A, Raynaud M, de Barace C, Marcorelles P, Pasquier L, Blayau M, Espil C, Parent P, Journel H, Lazaro L, Andoni Urtizberea J, Moerman A, Faivre L, Eymard B, Maincent K, Gherardi R, Chaigne D, Ben Yaou R, Leturcq F, Chelly J, Desguerre I. Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age. <span><span class="ref-journal">Eur J Hum Genet. </span>2013;<span class="ref-vol">21</span>:855–63.</span> [<a href="/pmc/articles/PMC3722679/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3722679</span></a>] [<a href="/pubmed/23299919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23299919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mestroni.1999.181">Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A, Miocic S, Vatta M, Pinamonti B, Muntoni F, Caforio AL, McKenna WJ, Falaschi A, Giacca M, Camerini A. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. <span><span class="ref-journal">J Am Coll Cardiol. </span>1999;<span class="ref-vol">34</span>:181–90.</span> [<a href="/pubmed/10400009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10400009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.mohassel.2015">Mohassel P, B&#x000f6;nnemann CG. Limb-girdle muscular dystrophies. In: Darras BT, Jones HR Jr, Ryan MM, De Vivo DC. <em>Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach</em>. 2 ed. San Diego, CA: Academic Press; 2015;635-67.</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.monaco.1988.90">Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. <span><span class="ref-journal">Genomics. </span>1988;<span class="ref-vol">2</span>:90–5.</span> [<a href="/pubmed/3384440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3384440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.moxley.2005.13">Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:13–20.</span> [<a href="/pubmed/15642897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15642897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.muntoni.2003.731">Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. <span><span class="ref-journal">Lancet Neurol. </span>2003;<span class="ref-vol">2</span>:731–40.</span> [<a href="/pubmed/14636778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14636778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.nelson.2016.403">Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. <span><span class="ref-journal">Science. </span>2016;<span class="ref-vol">351</span>:403–7.</span> [<a href="/pmc/articles/PMC4883596/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4883596</span></a>] [<a href="/pubmed/26721684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26721684</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.neri.2007.913">Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, Spitali P, Rimessi P, Gualandi F, Sewry C, Ferlini A, Muntoni F. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. <span><span class="ref-journal">Neuromuscul Disord. </span>2007;<span class="ref-vol">17</span>:913–8.</span> [<a href="/pubmed/17826093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17826093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.neri.2012.20">Neri M, Valli E, Alfano G, Bovolenta M, Spitali P, Rapezzi C, Muntoni F, Banfi S, Perini G, Gualandi F, Ferlini A. The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy. <span><span class="ref-journal">BMC Med Genet. </span>2012;<span class="ref-vol">13</span>:20.</span> [<a href="/pmc/articles/PMC3331845/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3331845</span></a>] [<a href="/pubmed/22455600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22455600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.nigro.1990.271">Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. <span><span class="ref-journal">Int J Cardiol. </span>1990;<span class="ref-vol">26</span>:271–7.</span> [<a href="/pubmed/2312196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2312196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.nolan.2003.129">Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. <span><span class="ref-journal">Neuromuscul Disord. </span>2003;<span class="ref-vol">13</span>:129–32.</span> [<a href="/pubmed/12565910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12565910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.ortizlopez.1997.2434">Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. <span><span class="ref-journal">Circulation. </span>1997;<span class="ref-vol">95</span>:2434–40.</span> [<a href="/pubmed/9170407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9170407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.palmucci.2000.529">Palmucci L, Mongini T, Chiado-Piat L, Doriguzzi C, Fubini A. Dystrophinopathy expressing as either cardiomyopathy or Becker dystrophy in the same family. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">54</span>:529–30.</span> [<a href="/pubmed/10668737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10668737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.parker.2005.729">Parker AE, Robb SA, Chambers J, Davidson AC, Evans K, O'Dowd J, Williams AJ, Howard RS. Analysis of an adult Duchenne muscular dystrophy population. <span><span class="ref-journal">QJM. </span>2005;<span class="ref-vol">98</span>:729–36.</span> [<a href="/pubmed/16135534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16135534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.parks.2016.312">Parks M, Court S, Cleary S, Clokie S, Hewitt J, Williams D, Cole T, MacDonald F, Griffiths M, Allen S. Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage. <span><span class="ref-journal">Prenat Diagn. </span>2016;<span class="ref-vol">36</span>:312–20.</span> [<a href="/pmc/articles/PMC4864947/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4864947</span></a>] [<a href="/pubmed/26824862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26824862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.passamano.2012.121">Passamano L, Taglia A, Palladino A, Viggiano E, D'Ambrosio P, Scutifero M, Rosaria Cecio M, Torre V, De Luca F, Picillo E, Paciello O, Piluso G, Nigro G, Politano L. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. <span><span class="ref-journal">Acta Myol. </span>2012;<span class="ref-vol">31</span>:121–5.</span> [<a href="/pmc/articles/PMC3476854/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3476854</span></a>] [<a href="/pubmed/23097603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23097603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.pegoraro.1995.677">Pegoraro E, Schimke RN, Garcia C, Stern H, Cadaldini M, Angelini C, Barbosa E, Carroll J, Marks WA, Neville HE, Marks H, Appleton S, Toriello H, Wessel HB, Donnelly J, Bernes SM, Taber JW, Weiss L, Hoffman EP. Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. <span><span class="ref-journal">Neurology. </span>1995;<span class="ref-vol">45</span>:677–90.</span> [<a href="/pubmed/7723955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7723955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.prior.2005.317">Prior TW, Bridgeman SJ. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. <span><span class="ref-journal">J Mol Diagn. </span>2005;<span class="ref-vol">7</span>:317–26.</span> [<a href="/pmc/articles/PMC1867542/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1867542</span></a>] [<a href="/pubmed/16049303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16049303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.quinlivan.2005.72">Quinlivan R, Roper H, Davie M, Shaw NJ, McDonagh J, Bushby K. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:72–9.</span> [<a href="/pubmed/15639124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15639124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.rall.2012.117">Rall S, Grimm T. Survival in Duchenne muscular dystrophy. <span><span class="ref-journal">Acta Myol. </span>2012;<span class="ref-vol">31</span>:117–20.</span> [<a href="/pmc/articles/PMC3476855/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3476855</span></a>] [<a href="/pubmed/23097602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23097602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.raymond.2010.674">Raymond FL, Whittaker J, Jenkins L, Lench N, Chitty LS. Molecular prenatal diagnosis: the impact of modern technologies. <span><span class="ref-journal">Prenat Diagn. </span>2010;<span class="ref-vol">30</span>:674–81.</span> [<a href="/pubmed/20572117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20572117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.ricotti.2016.77">Ricotti V, Mandy WP, Scoto M, Pane M, Deconinck N, Messina S, Mercuri E, Skuse DH, Muntoni F. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. <span><span class="ref-journal">Dev Med Child Neurol. </span>2016;<span class="ref-vol">58</span>:77–84.</span> [<a href="/pubmed/26365034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26365034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.saito.1996.642">Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. <span><span class="ref-journal">Am Heart J. </span>1996;<span class="ref-vol">132</span>:642–7.</span> [<a href="/pubmed/8800037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8800037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.schade_van_westrum.2011.62">Schade van Westrum SM, Hoogerwaard EM, Dekker L, Standaar TS, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, van Essen AJ, Leschot NJ, Wilde AA, de Haan RJ, de Visser M, van der Kooi AJ. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. <span><span class="ref-journal">Neurology. </span>2011;<span class="ref-vol">77</span>:62–6.</span> [<a href="/pubmed/21700587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21700587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.shimizu.2005.150">Shimizu M, Ino H, Yasuda T, Fujino N, Uchiyama K, Mabuchi T, Konno T, Kaneda T, Fujita T, Masuta E, Katoh M, Funada A, Mabuchi H. Gene mutations in adult Japanese patients with dilated cardiomyopathy. <span><span class="ref-journal">Circ J. </span>2005;<span class="ref-vol">69</span>:150–3.</span> [<a href="/pubmed/15671604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15671604</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.soltanzadeh.2010.499">Soltanzadeh P, Friez MJ, Dunn D, von Niederhausern A, Gurvich OL, Swoboda KJ, Sampson JB, Pestronk A, Connolly AM, Florence JM, Finkel RS, B&#x000f6;nnemann CG, Medne L, Mendell JR, Mathews KD, Wong BL, Sussman MD, Zonana J, Kovak K, Gospe SM Jr, Gappmaier E, Taylor LE, Howard MT, Weiss RB, Flanigan KM. Clinical and genetic characterization of manifesting carriers of DMD mutations. <span><span class="ref-journal">Neuromuscul Disord. </span>2010;<span class="ref-vol">20</span>:499–504.</span> [<a href="/pmc/articles/PMC2944769/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2944769</span></a>] [<a href="/pubmed/20630757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20630757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.sumita.1998.356">Sumita DR, Vainzof M, Campiotto S, Cerqueira AM, Canovas M, Otto PA, Passos-Bueno MR, Zatz M. Absence of correlation between skewed X inactivation in blood and serum creatine-kinase levels in Duchenne/Becker female carriers. <span><span class="ref-journal">Am J Med Genet. </span>1998;<span class="ref-vol">80</span>:356–61.</span> [<a href="/pubmed/9856563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9856563</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.tabebordbar.2016.407">Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA, Cong L, Zhang F, Vandenberghe LH, Church GM, Wagers AJ. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. <span><span class="ref-journal">Science. </span>2016;<span class="ref-vol">351</span>:407–11.</span> [<a href="/pmc/articles/PMC4924477/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4924477</span></a>] [<a href="/pubmed/26721686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26721686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.takeshima.2010.379">Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, Nishio H, Matsuo M. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. <span><span class="ref-journal">J Hum Genet. </span>2010;<span class="ref-vol">55</span>:379–88.</span> [<a href="/pubmed/20485447" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20485447</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.tangsrud.1989.100">Tangsrud SE, Halvorsen S. Child neuromuscular disease in southern Norway. The prevalence and incidence of Duchenne muscular dystrophy. <span><span class="ref-journal">Acta Paediatr Scand. </span>1989;<span class="ref-vol">78</span>:100–3.</span> [<a href="/pubmed/2784019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2784019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.taylor.2010.e8803">Taylor PJ, Betts GA, Maroulis S, Gilissen C, Pedersen RL, Mowat DR, Johnston HM, Buckley MF. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. <span><span class="ref-journal">PLoS One. </span>2010;<span class="ref-vol">5</span>:e8803.</span> [<a href="/pmc/articles/PMC2808359/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2808359</span></a>] [<a href="/pubmed/20098710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20098710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.towbin.1998.131">Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. <span><span class="ref-journal">Curr Opin Cell Biol. </span>1998;<span class="ref-vol">10</span>:131–9.</span> [<a href="/pubmed/9484605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9484605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.towbin.2003.317">Towbin JA. A noninvasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy? <span><span class="ref-journal">J Am Coll Cardiol. </span>2003;<span class="ref-vol">42</span>:317–8.</span> [<a href="/pubmed/12875770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12875770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.towbin.1993.1854">Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, McCabe ER, Swift M. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. <span><span class="ref-journal">Circulation. </span>1993;<span class="ref-vol">87</span>:1854–65.</span> [<a href="/pubmed/8504498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8504498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.tufferygiraud.2009.934">Tuffery-Giraud S, B&#x000e9;roud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Coss&#x000e9;e M, Boisseau P, Blayau M, Creveaux I, Guiochon-Mantel A, de Martinville B, Philippe C, Monnier N, Bieth E, Khau Van Kien P, Desmet FO, Humbertclaude V, Kaplan JC, Chelly J, Claustres M. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:934–45.</span> [<a href="/pubmed/19367636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19367636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.van_essen.1992.258">van Essen AJ, Busch HF, te Meerman GJ, ten Kate LP. Birth and population prevalence of Duchenne muscular dystrophy in The Netherlands. <span><span class="ref-journal">Hum Genet. </span>1992;<span class="ref-vol">88</span>:258–66.</span> [<a href="/pubmed/1733827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1733827</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.van_essen.2003.296">van Essen AJ, Mulder IM, van der Vlies P, van der Hout AH, Buys CH, Hofstra RM, den Dunnen JT. Detection of point mutation in dystrophin gene reveals somatic and germline mosaicism in the mother of a patient with Duchenne muscular dystrophy. <span><span class="ref-journal">Am J Med Genet. </span>2003;<span class="ref-vol">118A</span>:296–8.</span> [<a href="/pubmed/12673664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12673664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.viggiano.2016.685">Viggiano E, Ergoli M, Picillo E, Politano L. Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy. <span><span class="ref-journal">Hum Genet. </span>2016;<span class="ref-vol">135</span>:685–98.</span> [<a href="/pubmed/27098336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27098336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.viggiano.2017">Viggiano E, Picillo E, Ergoli M, Cirillo A, Del Gaudio S, Politano L. Skewed X-chromosome inactivation plays a crucial role in the onset of symptoms in carriers of Becker muscular dystrophy. <span><span class="ref-journal">J Gene Med. </span>2017;<span class="ref-vol">19</span>(4)</span> [<a href="/pubmed/28316128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28316128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.viollet.2012.98">Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. <span><span class="ref-journal">Am J Cardiol. </span>2012;<span class="ref-vol">110</span>:98–102.</span> [<a href="/pubmed/22463839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22463839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.wagner.2008.561">Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>2008;<span class="ref-vol">63</span>:561–71.</span> [<a href="/pubmed/18335515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18335515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.wagner.2002.832">Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. <span><span class="ref-journal">Ann Neurol. </span>2002;<span class="ref-vol">52</span>:832.</span> [<a href="/pubmed/12447939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12447939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.wang.2017.356">Wang H, Xu Y, Liu X, Wang L, Jiang W, Xiao B, Wei W, Chen Y, Ye W, Ji X. Prenatal diagnosis of Duchenne muscular dystrophy in 131 Chinese families with dystrophinopathy. <span><span class="ref-journal">Prenat Diagn. </span>2017;<span class="ref-vol">37</span>:356–64.</span> [<a href="/pubmed/28181689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28181689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.watkins.2011.1643">Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:1643–56.</span> [<a href="/pubmed/21524215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21524215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.welch.2007.87">Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">447</span>:87–91.</span> [<a href="/pubmed/17450125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17450125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.white.2002.365">White S, Kalf M, Liu Q, Villerius M, Engelsma D, Kriek M, Vollebregt E, Bakker B, van Ommen GJ, Breuning MH, den Dunnen JT. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:365–74.</span> [<a href="/pmc/articles/PMC379168/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379168</span></a>] [<a href="/pubmed/12111668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12111668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.white.2006.938">White SJ, Aartsma-Rus A, Flanigan KM, Weiss RB, Kneppers AL, Lalic T, Janson AA, Ginjaar HB, Breuning MH, den Dunnen JT. Duplications in the DMD gene. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:938–45.</span> [<a href="/pubmed/16917894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16917894</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.wicksell.2004.154">Wicksell RK, Kihlgren M, Melin L, Eeg-Olofsson O. Specific cognitive deficits are common in children with Duchenne muscular dystrophy. <span><span class="ref-journal">Dev Med Child Neurol. </span>2004;<span class="ref-vol">46</span>:154–9.</span> [<a href="/pubmed/14995084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14995084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.wingeier.2011.90">Wingeier K, Giger E, Strozzi S, Kreis R, Joncourt F, Conrad B, Gallati S, Steinlin M. Neuropsychological impairments and the impact of dystrophin mutations on general cognitive functioning of patients with Duchenne muscular dystrophy. <span><span class="ref-journal">J Clin Neurosci. </span>2011;<span class="ref-vol">18</span>:90–5.</span> [<a href="/pubmed/21109441" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21109441</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.xu.2015.889">Xu Y, Li X, Ge HJ, Xiao B, Zhang YY, Ying XM, Pan XY, Wang L, Xie WW, Ni L, Chen SP, Jiang WT, Liu P, Ye H, Cao Y, Zhang JM, Liu Y, Yang ZJ, Chen YW, Chen F, Jiang H, Ji X. Haplotype-based approach for noninvasive prenatal tests of Duchenne muscular dystrophy using cell-free fetal DNA in maternal plasma. <span><span class="ref-journal">Genet Med. </span>2015;<span class="ref-vol">17</span>:889–96.</span> [<a href="/pubmed/25654318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25654318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.yan.2004.203">Yan J, Feng J, Buzin CH, Scaringe W, Liu Q, Mendell JR, den Dunnen J, Sommer SS. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:203–4.</span> [<a href="/pubmed/14722924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14722924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.yazaki.1999.145">Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N, Ikeda S. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. <span><span class="ref-journal">Eur Neurol. </span>1999;<span class="ref-vol">42</span>:145–9.</span> [<a href="/pubmed/10529540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10529540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.yoshida.1998.1129">Yoshida K, Nakamura A, Yazaki M, Ikeda S, Takeda S. Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:1129–32.</span> [<a href="/pubmed/9618170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9618170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.zalaudek.1999.1975">Zalaudek I, Bonelli RM, Koltringer P, Reisecker F, Wagner K. Early diagnosis in Duchenne muscular dystrophy. <span><span class="ref-journal">Lancet. </span>1999;<span class="ref-vol">353</span>:1975.</span> [<a href="/pubmed/10371601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10371601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dbmd.REF.zatz.1991.190">Zatz M, Rapaport D, Vainzof M, Passos-Bueno MR, Bortolini ER, Pavanello R de C, Peres CA. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. <span><span class="ref-journal">J Neurol Sci. </span>1991;<span class="ref-vol">102</span>:190–6.</span> [<a href="/pubmed/2072118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2072118</span></a>]</div></li></ul></div></div><div id="dbmd.Chapter_Notes"><h2 id="_dbmd_Chapter_Notes_">Chapter Notes</h2><div id="dbmd.Acknowledgments"><h3>Acknowledgments</h3><p>The authors would like to thank Elizabeth DeChene, MS, CGC, and Elicia Estrella, MS, CGC, of the Program in Genomics/Harvard Neuromuscular Disease Project, Children's Hospital Boston, for their assistance in reviewing and editing the Genetic Counseling Section.</p></div><div id="dbmd.Author_History"><h3>Author History</h3><p>Basil T Darras, MD (1999-present)<br />Partha S Ghosh, MD (2018-present)<br />Bruce R Korf, MD, PhD, FACMG; University of Alabama-Birmingham (1999-2011)<br />David T Miller, MD, PhD, FACMG; Boston Children&#x02019;s Hospital (2011-2018)<br />David K Urion, MD (1999-present)</p></div><div id="dbmd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>26 April 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 November 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 November 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 March 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 August 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 October 2004 (cd) Revision</div></li><li class="half_rhythm"><div>3 August 2004 (cd) Revision: Management</div></li><li class="half_rhythm"><div>24 March 2004 (cd) Revision: Diagnosis</div></li><li class="half_rhythm"><div>23 June 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 September 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>December 1999 (bk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1119</span><span class="label">PMID: <a href="/pubmed/20301298" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301298</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ebd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eed-og/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1119&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1119/?report=reader">PubReader</a></li><li><a href="/books/NBK1119/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1119" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1119" style="display:none" title="Cite this Page"><div class="bk_tt">Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. 2000 Sep 5 [Updated 2018 Apr 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1119/pdf/Bookshelf_NBK1119.pdf">PDF version of this page</a> (593K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#dbmd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#dbmd.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#dbmd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#dbmd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#dbmd.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#dbmd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#dbmd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#dbmd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#dbmd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#dbmd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#dbmd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#dbmd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1756[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DMD</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1486306" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1486306" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1486306" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1486306" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301609" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bonne G, Leturcq F, Ben Yaou R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301604" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Achermann JC, Vilain EJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21634085" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Herbert M, Goldstein JL, Rehder C, Austin S, Kishnani PS, Bali DS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301567" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Otopalatodigital Spectrum Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Otopalatodigital Spectrum Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Robertson S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301298" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301298" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0410e275f66d18aad95917">Dystrophinopathies - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Dystrophinopathies - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:46:10-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CAD00E03FDC7100000000079B02AE&amp;ncbi_session=CE8CAD00E0410E21_1947SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1119%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1119&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1119/&amp;ncbi_pagename=Dystrophinopathies - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CAD00E0410E21_1947SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>